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Cardiovascular disease burden 
 
Cardiovascular disease (CVD) is the main cause of death worldwide (1). Within Europe, CVD 
is responsible for 3.9 million deaths each year, which is 45% of all annual deaths (2). More 
women die from CVD compared to men; 49% versus 40% of all deaths (2). CVD causes a loss 
of 64 million disability-adjusted life years (DALYs), accounting for 23% of all DALYs lost across 
Europe in 2015 (2, 3). The burden of CVD results in high total costs for the European Union 
economy of approximately €210 billion a year, in terms of direct health care costs, productivity 
losses and care of patients with CVD (2).  
 
In the Netherlands, CVD is the second most common cause of death after cancer in both women 
and men until the age of 85 years: then CVD becomes leading cause of death (4). In 2017, CVD 
mortality accounted for 25% of all-cause mortality in the Netherlands (Table 1). The proportion 
of CVD-related deaths was comparable in both men and women; 25% and 26% respectively. 
However, also in the Netherlands the absolute number of women who died from CVD is higher 
compared to men; 20,039 women and 18,080 men. The main explanation for this difference is 
the higher proportion of women in higher age groups where the risk of CVD is higher. This is 
also reflected in the mean age at CVD-related death which is 78 years for men and 84 years for 
women (4) (Table 1).  
 
Of all different types of CVD, coronary heart disease (CHD) is the main cause of CVD burden 
in Europe. In the European Union, 632,000 people died from CHD and 3.1 million people were 
admitted to the hospital in 2015 (2). In the Netherlands, 72,336 people were admitted to the 
hospital due to CHD in 2017, which was 27% of all CVD-related hospital admissions. Of those 
who were admitted to the hospital with CHD-related causes, 49,375 were men and 22,961 were 
women. Considerably more men died from CHD than women: 4,983 men (28% of CVD-related 
deaths) versus 3,350 women (17% of CVD-related deaths) (4).  
 
Table 1. Causes of death in the Netherlands in 2017.  
 
Causes of death 
Men   Women   Total  
N (%)* Mean age 
at death 
 N (%)* Mean age 
at death 
 N (%)* Mean age 
at death 
Cardiovascular diseases 18,080 (25) 78  20,039 (26) 84  38,119 (25) 81 
Cancer  24,532 (34) 73  20,353 (26) 73  44,885 (30) 73 
Respiratory diseases 6,305 (9) 80  6,647 (9) 82  12,952 (9) 81 
Psychological and behavioral 
disorders 
4,387 (6) 82  8,194 (11) 87  12,581 (8) 85 
Nervous system disorders 3,723 (5) 77  4,753 (6) 82  8,476 (6) 80 
External causes of injury and 
poisoning 
4,159 (6) 65  3,810 (5) 79  7,969 (5) 71 
Other causes 11,475 (16) 73  13,757 (18) 81  25,232 (17) 78 
All causes 72,661 (100) 75  77,553 (100) 80  150,214 (100) 78 
Adapted from the Dutch Heart Foundation (4). 






In recent years, cardiovascular mortality has decreased in most of the high-income countries of 
Western Europe (3, 4). However, the burden of CVD remains serious as the absolute number 
of CVD cases has increased (2). This is a consequence of several causes, including an increase in 
life expectancy, a growth in total population size and in the number of elderly people (5, 6). Only 
a slight decrease in the age-standardized CVD prevalence is observed when controlling for 
changes in population size and composition (2). Another alarming element in the high CVD 
burden is the continuous increase in the prevalence of cardiovascular risk factors (7). Therefore, 




Atherosclerosis is the predominant process in the development of CVD. The onset of this 
process starts early in life and progresses during life. Fatty streaks, which are the first visible 
manifestation of atherosclerosis, are present in almost all Western children. These streaks are 
often the initial lesion of atherosclerosis as they can progress asymptomatically into 
atherosclerotic plaques (8). During this progression, calcium deposits are formed in coronary 
arteries (9). Plaques often remain clinically unapparent for decades. However, this stage is a 
serious health threat in many cases. The atherosclerotic plaque eventually can obstruct the blood 
flow and can become detached causing an obstruction elsewhere in the body (10). Unfortunately, 
the first clinical manifestation of the disease occurs when an artery is already largely or completely 
blocked. This can result in serious event as myocardial infarction, stroke or even sudden cardiac 
death. Although the pathogenesis of atherosclerosis has not been fully clarified yet, it is known 
that the process is associated with CVD risk factors (10).  
 
The main CVD risk factors are smoking, age, male sex and a family history of CVD. Moreover, 
unhealthy lifestyles, including limited physical activity and unhealthy diet, can cause obesity, 
diabetes mellitus, hypercholesterolemia and hypertension. Unfortunately, the prevalence of 
unhealthy lifestyles is high. A survey from the European Action on Secondary and Primary 
Prevention by Intervention to Reduce Events (EUROASPIRE) IV in primary care was carried 
out in 71 centers from 14 European countries in 2014 and 2015. Of the 6700 reviewed 
asymptomatic patients who were prescribed treatment, 16.6% were smokers, 39.9% were 
overweight (body mass index (BMI)≥25 and <30 kg/m2), 43.5% obese (BMI ≥30 kg/m2) and 
63.9% centrally obese (waist circumference of ≥88 cm for women, ≥102 cm for men) (7). These 
risk factors and conditions are not only directly related to development of atherosclerosis and 
CVD, but also to morbidity and mortality from other causes such as cancer and respiratory 
diseases (11, 12). Improvement of the modifiable risk factors can prevent development of CVD. 
Despite a reduction in the percentage of current smokers, the prevalence of obesity and diabetes 
mellitus has increased substantially (13, 14). As a result, development of atherosclerosis is not 









Prevention of diseases can target different stages of the disease development process. First, 
primary prevention aims to hinder the development of disease before health effects can occur. 
Primary prevention measures include vaccinations, altering risk behavior, and health education 
in the general population. Then, secondary prevention is early detection of a preclinical disease 
phase so that early treatment can prevent or delay the onset of disease symptoms. Population-
based screening programs can identify the asymptomatic individuals with preclinical disease. 
Last, tertiary prevention focuses on the stage in which the disease has manifested. The aim is to 
halt disease progression and improve survival and quality of life. As many other diseases, 
prevention of CVD can also be targeted at the above described prevention levels.  
 
The main goal of CVD prevention is to improve the modifiable risk factors by adopting a healthy 
lifestyle and/or starting preventive drug treatment (15, 16). In general, lifestyle interventions 
apply to every individual. Lifestyle advice includes: 
 Smoking cessation; CVD risk begins to reduce within six months after abstinence 
and approaches the risk of non-smokers after ten to fifteen years (17). 
 Healthy balanced diet; CVD risk can be reduced by a Mediterranean diet consisting 
of daily consumption of vegetables, fruits, whole grains and healthy (unsaturated) 
fats, weekly intake of fish, poultry, beans and eggs, moderate consumption of dairy 
products and alcohol, and limited intake of red meat and salt (18).  
 Regular physical activity; physical activity not only reduces CVD mortality but also 
all-cause mortality. It improves body weight, hypertension, cholesterol, diabetes 
mellitus and mental health (19).  
 
Besides lifestyle change recommendations, initiation of drug treatment may be considered for 
preventing CVD events. Drug treatment is aimed at lowering lipids and blood pressure. Lipid-
lowering drugs include statins which reduce CVD morbidity and mortality by decreasing low-
density lipoprotein cholesterol (LDL-C) (20, 21). Statins are the first choice in patients with 
hypercholesterolemia as they are able to halt progression of coronary atherosclerosis when dosed 
to reduce LDL-C by at least 50% (22). Statin use can achieve a relative reduction in CVD 
mortality of 31% according to pooled results from 19 randomized-controlled trials (RCT) (23). 
Combination treatment may be required when treatment goals cannot be reached with one single 
drug. Additionally, reduction of blood pressure using antihypertensive drugs is effective as well 
in decreasing CVD risk. All major blood pressure lowering drugs are effective in reducing CHD-
related events with about 25% when systolic blood pressure is lowered by 10 mmHg (24).  
 
Primary CVD prevention, offered by national governments, focuses mainly on improving the 
lifestyle-related risk factors. Educational programs and smoking cessation interventions are 
promoted and available for the general population. Currently, the Dutch guideline for 
Cardiovascular Risk Management (CVRM) of the Dutch College of General Practitioners 
(NHG) advises a combination of opportunistic and systematic screening to detect at-risk 




has no predefined strategy and takes place when the opportunity arises. Systematic screening 
involves actively inviting a specific subgroup of the general population for screening. However, 
as systematic screening is time-consuming for general practitioners (GP), not every at-risk 
individual will be identified using this strategy.  
 
As described above, cardiovascular mortality has decreased in recent years. This may be 
explained by improved prevention in terms of risk factor control and better treatment. Changes 
in risk factors can rapidly cause substantial declines in mortality (27, 28). A CHD model 
(IMPACT) estimated that approximately half of the CHD mortality decrease is attributable to 
risk factor reduction and also approximately half to improved treatment (29). Despite the 
mortality decline, increases in the prevalence of obesity and diabetes mellitus maintain the high 
ongoing CVD burden. Prevention of CVD remains a high priority to reduce morbidity and 
mortality, and to reduce the burden on quality of life, health care systems and economy (30).  
 
Currently, one of the problems in CVD prevention is that a large proportion of the population 
is missed for preventive measures. A substantial number of individuals who might benefit from 
prevention remains unidentified. Primary prevention is proven to be effective in reducing 
morbidity and mortality of CVD, however, effects of these prevention strategies are often 
limited. The preventive measures are not targeted directly to at-risk subgroups and moreover, 
not all at-risk subjects feel addressed by the general preventive measures. Furthermore, adjusting 
lifestyle and adhering to preventive treatment is known to be challenging (31). The 
EUROASPIRE IV survey showed that CVD prevention guidelines to reduce unhealthy lifestyles 
in high-risk individuals are poorly followed (7). Prevention often needs to be initiated when there 
are no symptoms yet. This makes it difficult to comprehend that prevention is actually important.  
 
The availability of effective and affordable risk-reducing medication offers opportunities for a 
screening program for the early detection and treatment of an increased risk of CVD. Since 
CHD is often asymptomatic for a long time until serious events occur, secondary prevention 
may be a good strategy (15, 32). This calls for research into whether screening contributes to 
lowering CVD morbidity and mortality. Currently, it is still unclear whether early identification 
of individuals at high risk of CVD followed by early treatment is actually effective, although 
positive effects are reported (33). It should be investigated which risk assessment method is most 
appropriate as screening tool assessing the risk of CVD in asymptomatic individuals. Moreover, 
advantages and disadvantages must be balanced and effectiveness needs to be demonstrated by 
analyzing potential morbidity and mortality reductions caused by early treatment of modifiable 
risk factors with lifestyle changes and/or preventive drug treatment.  
 
Screening for cardiovascular diseases 
 
As stated before, screening aims to stop or delay subclinical disease progression to prevent or 
postpone serious events (Figure 1). The early development of atherosclerosis provides a chance 
to detect and treat progression in an early phase, leading to gains in healthy life years and survival. 




Figure 1. Effect of screening by detecting subclinical disease to prevent or delay disease progression.  
 
for developing CVD who can benefit from starting preventive treatment. The availability of a 
detection tool is essential to perform a reliable risk assessment (34). There are a few risk 
assessment tools that may be suitable as a screening tool.  
 
Traditional risk assessment 
Traditionally, identification of individuals at high risk for developing CVD is based on 
assessment of the main risk factors. Several risk prediction models use these risk factors to 
calculate the absolute risk of (non-)fatal CVD, for example in the Systematic Coronary Risk 
Evaluation (SCORE) and the Framingham Heart Score (15, 35, 36). The SCORE model includes 
age, sex, smoking status, diabetes mellitus status, systolic blood pressure, and total and high-
density lipoprotein cholesterol. The absolute risk scores are categorized into three risk categories: 
low, intermediate and high risk (Figure 2). Based on the calculated risk, GPs can distinguish who 
requires lifestyle interventions and/or preventive drug treatment. The 2011 edition of the Dutch 
CVRM-guideline advises SCORE calculation for identification of individuals who are expected 
to be at high 10-years risk for developing fatal and/or non-fatal CVD (25) (Figure 2a). In 2019, 
an update of the guideline became available. This edition differs from the previous on several 
subjects. The most important adjustment is the SCORE table itself. Cardiovascular mortality risk 
and cardiovascular morbidity risk are displayed separately. The mortality risk is leading in 
determining the risk category. The morbidity risk is represented by a range instead of one risk 
percentage, as the morbidity risk estimate is more uncertain than the mortality risk estimate. This 
risk of morbidity can be used to discuss the CVD risk with the patient (26) (Figure 2b). Since 
the research in this thesis was conducted before 2019, the previous edition of the CVRM-
guideline is integrated in this thesis. 
 
Risk profiling is advised in specific subgroups, for example individuals with diagnosed CVD, 
diabetes mellitus, kidney disease, a family history of CVD, or one or more risk factors. 
Advantages of the SCORE model are its ease of use, objectiveness, and it provides a common 
language for healthcare professionals. However, the SCORE model is limited for different ethnic 
groups and age ranges (15). Moreover, it has limited accuracy to predict the correct risk status. 
Especially the classification of intermediate risk is uncertain, as there are intermediate-risk 
individuals who are actually at higher risk and require a higher level of prevention. On the other 
hand, the intermediate risk category also includes lower risk individuals who might not need 
preventive drug treatment. The SCORE model cannot sufficiently distinguish between these two 
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Figure 2. A. Risk table for estimating 10-years risk for developing fatal and/or non-fatal cardiovascular diseases based 
on the Systematic Coronary Risk Evaluation model in the Netherlands (Dutch guideline for Cardiovascular Risk 
Management of the Dutch College of General Practitioners, edition 2011 (25)). B. Risk table for estimating 10-years risk 
for developing fatal (in bold) and non-fatal (in italic) cardiovascular diseases based on the Systematic Coronary Risk 
Evaluation model in the Netherlands (Dutch guideline for Cardiovascular Risk Management of the Dutch College of 
General Practitioners, edition 2019 (26)). 
 
Coronary artery calcium quantification 
Coronary artery calcium (CAC) is argued to be a more accurate risk predictor than traditional 
risk models (38-41). CAC is strongly associated with major cardiovascular events in 
asymptomatic individuals, in all races, age groups, and both sexes (42). Previous research has 
shown that individuals without traditional risk factors but elevated CAC have a substantially 
higher event rate than those who have multiple risk factors but no CAC (43). The development 
of coronary artery calcifications is a pathogenic process that is stimulated by several 
developmental, inflammatory, and metabolic factors (44). The amount of CAC can be quantified 
using low-dose computed tomography (CT) scanning of the coronary arteries and is expressed 
as the CAC score (Agatston) (Figure 3) (45). Developments in CT scanning techniques facilitate 
non-invasive detection of CAC. The absolute CAC score provides an independent risk estimate 
and is often stratified in three risk groups according to cutoffs of 100 and 400 (46). A decision 




   
Figure 3. Computed tomography images of the chest for quantification of coronary artery calcification (CAC). Left: 
CAC score of 0, right: calcifications are highlighted in yellow; CAC score of ≥1000. 
 
earlier study showed that CAC scoring reclassified more than 50% of intermediate-risk elderly 
individuals as having either low or high risk of CHD events (47). The reclassification rate of the 
CAC score varied between 22 and 26% in three major population-based cohort studies: the 
Multi-Ethnic Study of Atherosclerosis, the Heinz Nixdorf Recall study, and the Rotterdam study 
(48). These studies showed the added value of adding CAC scoring to risk assessment. Another 
study identified CAC ≥ 100 as a valuable cutoff for considering preventive treatment, as 10-year 
event rates were consistently above 7.5% in persons with CAC  ≥ 100 (42). Furthermore, 
absence of CAC is associated with low event rates and confers a 15-year warranty period against 
mortality (42, 49). Based on the observational cohort studies, current CVD prevention guidelines 
now include statements regarding the application of CAC scoring. The European Society of 
Cardiology recommends systematic assessment of SCORE in increased risk individuals and 
additional CAC scoring in individuals with moderate SCORE in their guideline on cardiovascular 
disease prevention in clinical practice (15). The new 2019 guideline on primary prevention of 
CVD of the American College of Cardiology/American Heart Association recommends CAC 
scoring to guide decisions about preventive interventions in select adults, but not as a screening  
test for all (50, 51). In their 2019 guidelines for the Diagnosis and Management of Chronic 
Coronary Syndromes, the European Society of Cardiology reported that CAC score may be 
considered as a risk modifier in the assessment of CVD risk, since it has a net reclassification 
improvement of 66% over traditional risk factors (52). 
 
Large-scale RCTs to investigate the effectiveness of the use of either traditional risk factors or 
CAC scoring as screening tools are lacking. Information about the balance between advantages 
and disadvantages is needed to determine the net (cost-)effectiveness of screening in reducing 
CVD-related morbidity and mortality. Prospective RCTs are also necessary to potentially 
demonstrate the added value of CAC scoring in subgroups from the risk population (53, 54). 





The ROBINSCA trial 
 
The largest population-based RCT on screening for a high risk of cardiovascular diseases was 
initiated in 2014: the Risk Or Benefit IN Screening for CArdiovascular diseases (ROBINSCA) 
trial. The primary objectives of this trial are: 
1. To establish whether screening for CVD by ‘classic’ risk factor assessment in 
asymptomatic men and women followed by early treatment according to prevailing 
guidelines will reduce CHD mortality and morbidity with at least 15% compared with 
no screening after 5-years of follow up.  
2. To establish whether screening for CAC using CT in asymptomatic men and women 
followed by early treatment according to prevailing guidelines will reduce CHD 
mortality and morbidity with at least 15% compared with screening with the ‘classic’ 
risk factor assessment after 5-years of follow-up (55).  
 
Women, aged 55-74 years, and men, aged 45-74 years, from the national population registry in 
the Netherlands were invited to participate in the ROBINSCA trial (Figure 4). They received an 
information brochure, a waist circumference measurement tape, a baseline risk questionnaire 
and a form to obtain written informed consent. Asymptomatic respondents free of diagnosed 
CVD but with a potentially increased CVD risk were eligible for participation. Eligible 
respondents who gave informed consent were randomized (1:1:1) to either the control arm, 
intervention arm A (screening according to the SCORE model, CVRM-guideline edition 2011), 
or intervention arm B (screening by means of determining the CAC score using CT (56)). Five 




Figure 4. Study regions of the ROBINSCA trial (figure from Vonder et al. (56)). Erasmus Medical Center (Rotterdam) 
is the coordinating center which investigates the primary and secondary outcomes. University Medical Center Groningen 






The primary outcome of the ROBINSCA trial is to investigate whether screening for CHD 
reduces CHD-related events in subjects at increased risk. Secondary outcomes include extended 
analyses of the primary outcome, sensitivity of the screening tests, reclassification of individuals 
in risk categories and corresponding change in treatments, contamination between study arms, 
impact of screening and the cost-effectiveness of screening. These outcomes will provide 
information that is required to investigate the balance between advantages and disadvantages of 
cardiovascular screening. Table 2 provides an overview of potential benefits and harms that need 
to be quantified.  
 
After 5-years of follow-up, primary outcomes will be investigated. Data will be collected through 
linkages with the causes of death registry and the national hospital discharge registry at Statistics 
Netherlands. Currently, the follow-up period is still ongoing. Several secondary outcomes are 
investigated using results of the screening test and additional participant questionnaires. The 
rationale of and the research conducted in the ROBINSCA trial is described in this thesis.  
 
Table 2. Potential benefits and harms from cardiovascular screening in the ROBINSCA trial.  
Benefits  Harms  
Reduction in CHD-related mortality False-positive test results 
Reduction in CHD-related morbidity Overtreatment 
Reduction in CHD-related hospital admissions Disruption of quality of life by fear and uncertainty 
Increase in (early) treatment options Radiation exposure  
Reduction of overall overtreatment Detection of other serious abnormalities 
Creating a teachable moment for a healthy lifestyle False reassurance  





Research questions  
 
This thesis aimed to evaluate several secondary outcomes of the ROBINSCA trial. The following 
research questions were formulated:  
1. How to conduct a population-based randomized-controlled screening trial to obtain 
evidence on the effectiveness of screening for cardiovascular risk in an asymptomatic 
high-risk population? 
2. What is the contamination rate in the study arms of the ROBINSCA trial? 
3. What are the differences in cardiovascular risk distributions and the number of 
preventive treatment indications between screening using traditional risk factor 
assessment or coronary artery calcium scoring in asymptomatic participants of the 
ROBINSCA trial? 
4. What is the coronary artery calcium prevalence and what are predictors in an 
asymptomatic potential high-risk target population for coronary artery calcium 
screening? 
5. What is the impact of receiving a cardiovascular disease risk screening result on 
preventive behavior and compliance to subsequent preventive treatment in 
asymptomatic participants of the ROBINSCA trial? 
 
Aims and outline of this thesis 
 
The research topics are divided in four parts. Part 1 focuses on background and power of the 
ROBINSCA trial. Chapter 2 discusses the rationale, study design and recruitment process of 
the trial in detail. In Chapter 3, the contamination rate is determined, defined as off-study 
screening, to assure statistical power to estimate the potential screening effectiveness. Part 2 
focuses on cardiovascular disease screening results. More specifically, Chapter 4 addresses the 
CVD risk distributions as assessed by both screening tools and estimates the potential reduction 
in preventive overtreatment based on the expected shift in CVD risk distribution. In Chapter 
5, the CAC prevalence in the asymptomatic high-risk population is investigated to evaluate the 
characteristics and predictors in this potential target population for screening. Part 3 addresses 
cardiovascular health behavior. Chapter 6 describes the impact of receiving a cardiovascular 
disease screening result on preventive behavior in participants.  Lastly, part 4 (Chapter 7) 
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Objectives: This article aims to describe the rationale, study design, and the recruitment process 
of the Dutch Risk or Benefit in Screening for Cardiovascular Disease (ROBINSCA) trial, 
worldwide the first population-based randomized-controlled Computed-Tomography (CT) 
screening trial for cardiovascular disease, powered to detect a benefit of 15% reduced Coronary 
Heart Disease (CHD) morbidity and mortality. 
Methods: Addresses of men (aged 45-74 years) and women (aged 55-74 years) were obtained 
(n=394,058) from the national population registry. All received a mailing with an information 
brochure, a questionnaire and waist measurement tape and an informed consent form. 
Asymptomatic people with an expected high-risk for developing CHD were included in this 
study: 1) a waist circumference of ≥ 102 cm (men) or ≥ 88 cm (women), 2) Body Mass Index of 
≥ 30 kg/m2, 3) current smoker and/or 4) a family history of CHD. Eligible respondents were 
Randomized (1:1:1) to one of the study arms: intervention arm A (screening traditional risk 
factors), intervention arm B (screening by Coronary Artery Calcium scoring only) or the control 
arm (usual care). Screened participants with a high risk for developing CHD were referred to the 
general practitioner for cardiovascular risk management. Linkages with national registries will be 
performed to measure (CHD-related) morbidity and mortality. 
Results: A total of 87,866 (22.3%) people responded to the questionnaire, of which 43,447 
(49.4%) were Randomized to intervention arm A (n=14,478 (33.3%)), intervention arm B 
(n=14,450 (33.3%)), or the control arm (n=14,519 (33.4%)). Of those who were considered to 
be ineligible, one had prior diagnosis of CHD (n=14,156), a medication for hypercholesterolemia 
and hypertension (n=13,670), no completed informed consent (n=4,490), previous 
cardiovascular surgery (n=4,146), and/or a CAC score within the last 12 months (n=393). 
Conclusion: Evidence for net-effectiveness of population-based screening for cardiovascular 








Coronary Heart Disease (CHD) remains a major cause of morbidity and mortality worldwide 
(1). As stated by the European Heart Network (EHN), about 20% (1.7 million deaths) of all-
cause mortality can be attributed to CHD in 2015. A further 17 million men and 13 million 
women suffered from CHD in 2015 and more than 35 million (14% in males; 11% in females) 
disability-adjusted life years (DALY) were lost due to CHD (2, 3). The total annual costs of CHD 
are considerable and estimated at €59 billion annually. About 32% (€18.9 billion) is due to health 
care costs, 33% (€19.8 billion) due to production losses and 35% (€20 billion) due to the informal 
care of people with CHD (3). 
 
Despite all medical advances last decades, one major concern is that CHD is often asymptomatic 
until the presentation of a serious event as myocardial infarction (MI) leading to persisting 
disability and/or premature death. The underlying process of (sub-clinical) atherosclerosis has 
one of the longest (stable) unrecognized courses, and therefore mainly untreated. Modifying 
cardiovascular disease (CVD)-related risk factors can prevent the vast majority of the CVD 
events (4). However, the combination of a high prevalence of unhealthy lifestyles as well as the 
suboptimal use of prevention measures and the ageing population remains a concern (3, 5). The 
rationale of screening is to halt or delay progression of the (subclinical) disease and thereby gain 
healthy life-years by offering treatment options at an earlier, yet undetected, and hopefully more 
efficacious stage. Although cost-effective preventive treatment options are available for 
cardiovascular diseases, there is no hard evidence from RCTs about whether the earlier detection 
of a high risk for developing CHD in the asymptomatic high-risk population indeed leads to 
earlier, more effective, less intensive treatment and therefore to health benefits in terms of 
reduced morbidity and mortality. 
 
The identification of asymptomatic people at risk of CVD relied almost exclusively on traditional 
risk factors to subsequently stratify individuals into low, intermediate, and high-risk to guide 
treatment decisions: age, gender, smoking habits, family history of CVD, Body Mass Index 
(BMI), lipids, and blood pressure (6, 7). However, the observation that the majority of coronary 
events occur in the intermediate risk group whose members are not considered candidates for 
intensive treatment as their high-risk counterparts calls for improvement in the risk stratification 
(8, 9). Computed Tomography (CT) enables the non-invasive detection and quantification of 
calcifications of coronary arteries (10). This Coronary Artery Calcium (CAC) score is argued to 
be useful by presenting an individualized cumulative lifetime risk exposure of (un)known risk 
factors, independently of traditional risk factors, but strongly related to both non-lethal major 
adverse cardiovascular events (such as myocardial infarction and stroke) and all-cause mortality, 
as shown by the Multi-Ethnic Study on Atherosclerosis (MESA) (11, 12), Framingham Heart 
Study (13) and Heinz Nixdorf Recall Study (14-16). Based on the total amount of coronary artery 
calcium (Agatston score) (17), CAC scoring seems to provide the opportunity for personalized 
risk assessment to identify those who might benefit most from preventive treatment. The net 
classification index after CAC scoring compared with traditional risk scoring implies the 




The European Guidelines on cardiovascular disease prevention in clinical practice only 
recommend systematic screening in those likely to be at high risk due to the presence of a family 
history of premature CVD, familial hypercholesterolemia, major CVD-related risk factors 
and/or co-morbidities (Class I recommendation; level of Evidence C) (18). The American 
College of Cardiology/American Heart Association (ACC/AHA) and European Society of 
Cardiology state that asymptomatic individuals at intermediate Framingham risk may be 
reasonable candidates for coronary calcification screening “when a risk-based decision to 
prescribe statins is uncertain after a patient-physician risk discussion”, whereas the American 
College of Preventive Medicine does not recommend routine screening in asymptomatic 
individuals using CT (7, 18-20). The IIb recommendation (“may be considered”) is mainly 
caused by the fact that data from large-scale RCTs, indicating that CAC screening for CHD will 
reduce CHD-related mortality and morbidity, are lacking. The EISNER (Early Identification of 
Subclinical Atherosclerosis by Noninvasive Imaging Research) trial is the only small RCT among 
2,137 (preferentially selected and higher educated) volunteers, comparing a group that did 
undergo CAC scanning before risk counselling or a control group that only had risk factor 
counselling (21). Randomization to CAC scanning was associated with superior CAD factor 
control on FRS, blood pressure, lipids, and medication after four years of follow-up. 
Unfortunately, the study was too small to have sufficient statistical power on hard events 
outcomes as CHD mortality and morbidity (22). 
 
There is an urgent need for large-scale population-based RCTs. Although this type of study 
requires a large amount of resources and time, it is the only way to provide evidence on the 
balance between potential benefits (reduction in CHD-related morbidity and mortality, 
reduction in overuse of statins and aspirin) and harms (radiation risk, overdiagnosis, 
overtreatment, and impact on quality of life) of CHD screening. The aim of this article is to 
describe the rationale, study design, and the recruitment process of the Dutch ROBINSCA (Risk 
or Benefit IN Screening for Cardiovascular disease) trial, a population-based randomized 





ROBINSCA study objectives 
The ROBINSCA trial is a 3-arms trial, designed 1) to investigate whether population-based 
screening for a high risk for developing cardiovascular heart diseases by SCORE followed by 
risk reducing treatment can reduce coronary artery disease-related morbidity and mortality with 
at least 15% compared to no screening amongst asymptomatic men and women after five years 
of follow-up and 2) to investigate whether population-based screening for a high risk for 
developing cardiovascular heart diseases by CAC scoring followed by risk reducing treatment 
can reduce coronary artery disease-related morbidity and mortality with at least 15% compared 
to screening by SCORE amongst asymptomatic men and women after five years of follow-up. 
 
 
The ROBINSCA trial: rationale and study design 
31 
Recruitment procedure 
To start the study, addresses of all men (aged 45-74 years) and women (aged 55-74 years) who 
lived in one of the three selected regions in The Netherlands were obtained (n=394,058) after a 
positive advice for a linkage with the national population registry (Figure 1). All selected people 
received a mailing with an information brochure, a questionnaire and waist measurement tape 
to examine eligibility and an informed consent form. The risk questionnaire was based on 
validated questionnaires to assess the CVD risk (23-25). The questionnaire contains items on 
age, gender, social-economic status (5- point scale), ethnicity, height, weight, waist 
circumference, CAC screening in the preceding year (yes/no), presence of chronic diseases and 
CVD (list: yes/no), surgery for CVD (list: yes/no), prescription of medication for hypertension/ 
hypercholesterolemia and/or diabetics (yes/no), list of prescribed medication, familial history of 
CVD (MI or sudden death) in first of second degree relatives before the age of 65 years (6-point 
scale), and current smoking behavior (smoking last week (yes/no), smoking duration (in years), 
smoking intensity (cigarettes/day)). 
 
Inhabitants received the information packet in Apeldoorn region in July 2014, in The Hague in 
October 2014 and in Groningen in June 2016. 
 
Selection of participants 
A respondent was considered to be eligible when one or more of the inclusion criteria were 
fulfilled, while none of the exclusion criteria were met. The inclusion criteria for ROBINSCA 
are a waist circumference of ≥ 102 cm (men) or ≥ 88 cm (women) (26), Body Mass Index of ≥ 
30 kg/m2, current smoker and/or a family history of MI or sudden death. 
 
Those who had already been diagnosed with cardiovascular disease (MI, heart attack, Cerebral 
Vascular Accident/Transient Ischemic Accident, heart failure, angina pectoris, aneurysm, 
stenosis of the carotid artery/femoral artery and atherosclerosis), who have had previous 
cardiovascular surgery (Coronary Artery Bypass Grafting, Percutaneous Coronary Intervention, 
or heart transplantation), who were on prescribed cholesterol lowering and blood pressure-
lowering drugs, who had a CAC scoring by CT scanning in the previous year and/or no complete 
informed consent form were excluded for participating in this study. Eligible respondents were 
Randomized (1:1:1) to intervention arm A, intervention arm B or the control arm (Figure 1). 
 
Screening 
Intervention arm A: Participants were invited to one of the local screening sites to measure their 
risk for developing cardiovascular diseases. A blood sample was taken to determine non-fasted 
cholesterol levels (Total Cholesterol level, High-Density Lipid-protein (HDL) Cholesterol level; 
mmol/l). Mean rested blood pressure (mmHg) was measured by two automatic consecutively 
measurements using an electronic blood pressure device (Microlife WatchBP Office, model 
TWIN200 AFS). 
 
The 10 years risk for fatal and non-fatal CVD was calculated using the SCORE risk table, as 





Figure 1. Flowchart of the recruitment, randomization and screening process in the ROBINSCA trial.  
Note: Smokers ≥ 50 years of age or with strong family history of CVD will be informed about their risk, as well as 
their GP. 
Abbreviations: BMI = Body Mass Index, CAC = Coronary Artery Calcium, CHD = Coronary Heart Disease, CT = 
Computed Tomography, CVD = Cardiovascular Disease, CVRM = Cardiovascular Risk Management, SCORE = 
Systematic Coronary Risk Evaluation 
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age, gender, smoking status, systolic blood pressure and Total Cholesterol/HDL-Cholesterol 
ratio). For those participants with established diabetes mellitus, the actual age was increased with 
15 years. Since data about diagnosed rheumatoid arthritis was considered to be invalid, there was 
no recalculation possible in these participants. A SCORE <10% indicates a low 10 years risk for 
developing CVD, whereas a SCORE of 10-20% were classified as a moderate risk and a SCORE 
of 20% or more as high risk. 
 
Intervention arm B: All participants Randomized in intervention arm B received an invitation for a 
CT scan to measure the CAC Score. The scanning protocol has been published previously (28). 
In brief, the CAC Score was measured using dual-source CT (DSCT) without the use of a 
contrast agent. According to participants’ weight and size (small/slender or large) the radiation 
dose exposure was adjusted automatically. The DSCT calcium scoring examination followed a 
scout view and was performed with prospective ECG-triggering. All scans were performed by 
experienced technicians, who were blinded to the clinical data of the participants. Quantification 
of coronary calcifications was performed with using dedicated CAC scoring software and the 
CAC scores were determined according to Agatston method (17) by multiplying each area of 
interest with a factor indicating peak density within the individual area. The effective dose of 
CAC screening (accounting for the sensitivity of exposed tissues) is 0.7-2 mSv, depending on 
the technology used. CAC scores were then divided into 29).  
 
Incidental findings in the chest or abdomen with expected clinical relevance (aortic aneurysm of 
≥ 50 mm, calcified pleural plaques and/or pleural fluid (≥ 2 cm thickness), large liver cyst(s) (≥ 
10 cm), identifiable abdominal mass) were reported at the general practitioner-after verifying that 
the participant gave their written informed consent (divided in serious incidental findings versus 
non-serious incidental findings). Incidental findings with no or limited clinical relevance (valve 
calcification (aortic valve, mitral valve, e.g.), valve calcification (aortic valve, mitral valve, e.g.), 
pericardial abnormalities (thickening, calcification, e.g.), hiatus hernia, small to medium size liver 
cyst(s)) were only reported at the screening site. 
 
Control arm: Study participants who were Randomized in the control arm received usual care (no 
screening). However, those aged above 55 years who currently smoked and those with a family 
history of CHD were prompted that they can ask for a risk scoring measurement by their GP, 
confirm the national guidelines for general practitioners (27). The GP was also informed about 
this message given to the participant. 
 
Referral and preventive treatment 
For participants of intervention group A, a SCORE of 10% and above indicated advice for 
referral to the GP for preventive treatment according to the Dutch guideline cardiovascular risk 
management for “patients without cardiovascular disease” from the Dutch College of General 
Practitioners (27). 
 
Participants in intervention group B with an Agatston score above 100 were referred to the GP 




possibly impact the clinical management of the CAC score. Information about the trial, the 
screening result and the recommended treatment was provided to all general practitioners. The 
advice for treatment was established in accordance with the current literature and in consultation 
of the research team and local cardiologists and GPs. The aim of the treatment study protocol 
was to keep it as close as possible to the current practice in primary care. Therefore, the 
recommended treatment comprises the prescription of ACE-inhibitors and statins. This is in 
line with the Dutch guideline cardiovascular risk management for “patients with CHD” from 
the Dutch College of General Practitioners (27). 
 
End points 
The primary outcome is to investigate whether screening for CHD in subjects at increased risk 
reduces CHD-events. A CHD event is defined as the first occurrence, within the follow-up 
period after randomization, of non-fatal or fatal coronary heart disease. These data will be 
collected through linkages with Causes of Death registry and National Hospital Discharge 
Registry at Statistics Netherlands. The underlying and contributory causes of death of 
participants who died will be retrieved through linkage with the Causes of Death Registry coded 
according to the International Classification of Deaths. In a subset of individuals, charts from 
the GPs and hospitals will be collected and reviewed by an independent committee to assess the 
validity of the official statistics, as has been done in our other RCTs (30, 31). 
 
Secondary outcomes 
Secondary outcomes measures include extensions of the primary outcome measures, sensitivity 
of the screening test(s), the reclassification of individuals in risk categories and corresponding 
change in treatments, the effects of CHD screening and cost-effectiveness. 
 
The effects of the interventions may have an effect on stroke as well. In an extended analysis, 
the rate of strokes in each arm will be incorporated in additional analyses as secondary outcome 
measure. Since fatal coronary heart disease is a large proportion of all deaths, differences in all-
cause mortality between arms will be analysed too. The sensitivity of the screen test will be 
evaluated using the 5-year follow-up data and equals the proportion of subjects who developed 
CHD and who were correctly identified as intermediate or high-risk participants by the 
conventional risk assessment (group 2) or by CAC score (group 3). The area under the receiver-
operating-characteristic curve, reclassification ratio, integrated sensitivity and specificity will be 
used as criterions for the performance of the tests (32). In the intervention arms, the change in 
risk estimates and distribution will be compared to the control arm. At the end of the follow-up 
period, questionnaires will be sent to the participants to ask for treatments received, compliance, 
lifestyle, risk perception, and impact of earlier diagnosis. The percentage of overtreatment 
and/or unnecessary treatments can be deducted. 
 
The favourable and unfavourable effects of CVD screening (Health- Related Quality of Life and 
health-related behaviour) are assessed in a random subsample of 5000 participants from 
randomization until 12 months after screening. 
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Power analysis 
The expected annual average event rate was estimated at 1.38%, based on data (year: 2008) for 
gender and age obtained from Statistics Netherlands. Based on previous population screening 
trials, the compliance rate in intervention group B was set on 90%, while the contamination rate 
of CT screening in intervention group A was set on 15%. This might be overestimated, since 
coronary calcium scoring is not part of the national guidelines for general practitioners. To reach 
a power of 80% to detect a 15% reduction in CHD under above mentioned conditions, a sample 
size of 13,028 was needed (Table 1). 
 
Some assumptions were made. The reduction in CHD that can be showed should be at least 
15% between intervention group B (CAC score) and intervention group A (SCORE). This 
implies that comparisons of intervention group A versus controls and intervention group B 
versus controls should also be possible. Reasons for a 15% reduction threshold derived from an 
estimated reclassification of about 35%, and the 
estimated higher risk categories due to screening by CAC scanning (8). Thereby, a population 




The study was approved by the Minister of Health, after a positive advice of the Dutch Health 
Council, because of the Dutch Population Screening Act. All participating centres gave their 
approval for conducting the study in the centres. Furthermore, the Minister of the Interior and 
Kingdom Relations gave permission to obtain all addresses from the Dutch population registry 
of men (aged 45-74 years) and women (aged 55-74 years) living in one of the three regions. 
 
Table 1. Power calculations under different conditions.  
CHD-event rate 




group 3 (%) 
Contamination of 
CAC-screening 
group 2 (%) N needed per arm 
1.17 15 95 5 10,682 
1.17 15 95 10 11,929 
1.17 15 95 15 13,414 
1.17 15 90 5 12,026 
1.17 15 90 10 13,524 
1.38 15 95 5 9,079 
1.38 15 90 10 11,496 
1.38 15 90 15 13,028 
1.17 20 90 20 9,554 
1.38 20 80 20 11,184 
CHD-event rate 




group 2 (%) 
Contamination of 
classic-screening 
group 1 (%) N needed per arm 
1.38 15 95 20 12,922 







Recruitment and randomization 
A total of 394,058 addresses of men and women living in Apeldoorn, The Hague or Groningen 
were obtained from the Dutch Population Registry of which 87,866 (22.3%) people responded 
to the questionnaire. Of the respondents, almost half (n=43,562; 49.6%) were considered to be 
eligible for participating in the ROBINSCA trial (Figure 1). In the region Apeldoorn and 
Groningen, 52.1% and 51.0% of the respondents were considered to be eligible respectively, 
whereas this was 44.4% of the respondents in the (most urban) region The Hague. Of those who 
were considered to be ineligible, most of them had prior diagnosis of CHD (n=14,156) and/or 
a prior prescription of both cholesterol as well as blood pressure lowering drugs (n=13,670). No 
informed consent or an incomplete informed consent form (n=14.7%), previous cardiovascular 
surgery (n=4,146), and/or a CAC score within the last 12 months (n=393) were reason for 
exclusion. A total of 114 eligibles were excluded just before randomization due to death, 
emigration, diagnosed/treated CHD or withdraw/unavailability. All other eligibles (n=43,447) 
were Randomized (1:1:1) to intervention arm A (n=14,478 (33.3%)), intervention arm B 
(n=14,450 (33.3%)), or the control arm (n=14,519 (33.4%)) (Figure 1). Baseline characteristics 
(gender, age, educational level, region, BMI, waist circumference, family history of myocardial 
infarction, smoking status, and diabetes mellitus) of study participants were comparable (p>0.05) 




Systematic population-based screening in an asymptomatic population is not yet recommended 
in (inter)national guidelines, although screening for several types of cancer has become a 
population screening strategy, despite the much lower incidence. The European Guidelines on 
cardiovascular disease prevention in clinical practice only recommend systematic screening in 
those likely to be at high risk due to the presence of a family history of premature CVD, familial 
hypercholesterolemia, major CVD-related risk factors and/or comorbidities (18). The American 
College of Cardiology/American Heart Association (ACC/AHA) and European Society of 
Cardiology stated that asymptomatic individuals at intermediate Framingham risk may be 
reasonable candidates for coronary calcification screening “when a risk-based decision to 
prescribe statins is uncertain after a patient-physician risk discussion”, whereas the American 
College of Preventive Medicine does not recommend routine screening in asymptomatic 
individuals using CT (7, 18-20). The IIb recommendation (“may be considered”) is mainly 
caused by the fact that data from large-scale RCTs, indicating that CAC screening for CHD will 
reduce CHD-related mortality and morbidity, are lacking.  
 
Long-term RCTs that evaluate hard end-points as morbidity and mortality are needed to 
overcome well-known biases of screening (lead-time and length time bias and overdiagnosis) in 
case of using survival rates as reflection of programmes’ effectiveness. Evidence for net-
effectiveness of population-based screening for cardiovascular risk in an asymptomatic 
population will enable large-scale implementation with possibly exceptionally large health gains.  
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Table 2. Baseline characteristics of study participants. 
  Control arm 
n/N (%) 
Intervention arm A 
n/N (%) 




Gender    0.866 
 Male 7044/14519 (51.5) 7456/14478 (51.5) 7480/14450 (51.8)  
 Female  7475/14519 (48.5) 7022/14478 (48.5) 6970/14450 (48.2)  
Age (median (IQR)) 61 (11) 61 (11) 61 (11) 0.696 
Educational level    0.492 
 Low  2899/14469 (20.0) 2980/14436 (20.6) 3007/14399 (20.9)  
 Medium  6476/14469 (44.8) 6419/14436 (44.5) 6307/14399 (43.8)  
 Higher  5094/14469 (35.2) 5037/14436 (34.9) 5022/14399 (34.9)  
Region     0.447 
 Apeldoorn 5858/14519 (40.3) 5855/14478 (40.4) 5887/14450 (40.7)  
 The Hague 3594/14519 (24.8) 3662/14478 (25.3) 3526/14450 (24.4)  
 Groningen 5067/14519 (34.9) 4961/14478 (34.3) 5037/14450 (34.9)  
Body Mass Index  
(median (IQR)) 
26.3 (5) 26.3 (5) 26.3 (5) 0.702 
Waist Circumference  
(median (IQR)) 
101.5 (14.4) 101.5 (14.5) 101.5 (14.5) 0.700 
Family history of CHD    0.269 
 No  7340/13302 (55.2) 7190/13223 (54.4) 7304/13213 (55.3)  
 Yes  5962/13302 (44.8) 6033/13223 (45.6) 5909/13213 (44.7)  
Smoking status    0.218 
 Former smoker 11420/14519 (78.7) 11503/14478 (79.5) 11454/14450 (79.3)  
 Current smoker 3099/14519 (21.3) 2975/14478 (20.5) 2996/14450 (20.7)  
Diabetes Mellitus    0.382 
 No  14055/14519 (96.8) 14009/14478 (96.8) 13949/14450 (96.5)  
 Yes 464/14519 (3.2) 469/ 14478 (3.2) 501/14450 (3.5)  
Abbreviations: CHD = Coronary Heart Disease, IQR = Interquartile Range 
 
This article presented the rationale, study design, and the results of the recruitment process of 
the Dutch large-scale population-based randomized-controlled screening trial for cardiovascular 
diseases: the ROBINSCA trial. 
 
Advantages of population-based recruitment over volunteer-based recruitment is that it is 
assumed that potential differences in background variables (morbidity and mortality, general 
health e.g.) are comparable between the study population and the target population (high-risk 
for developing CHD). But, self-selection might always be present. Thereby, it is well-known that 
less deprived are more likely to have higher risk, but they are less likely to attend screening or 
take part in trials, although the potentially high gain from screening (33). Future comparison of 
background characteristics between the study population (data from the questionnaire) and the 
general population (data from Statistics Netherlands) is warranted to estimate the 
representativeness of the study population. 
 
Another advantage of the population-based recruitment strategy is that those who were 
approached with the question to participate in the screening trial were unaware of the in- and 






Data of the ROBINSCA trial will provide more insight on the balance between the harms and 
benefits of screening for cardiovascular diseases. 
 
Recently, researchers of the Multi-Ethnic Study on Atherosclerosis found that the (absence of) 
an elevated CAC score is also associated with and increased risk for (the absence of) non-
cardiovascular disease (cancer, chronic kidney disease, chronic obstructive pulmonary disease 
and hip fractures), what suggest a more widespread use in risk prevention of multiple diseases 
(34). Now-a-days, CAC scoring on low-dose CT for lung cancer screening participants is also 
recommended in current guidelines (10). 
 
The obstruction of the coronary arteries is seldom not accompanied with an increased calcium 
score. In that perspective is a CAC of zero indicative for a low risk for CHD in the near future. 
The absence of CAC seems to be an overall marker for a process of healthy ageing due to the 
lower risk for not only developing cardiovascular diseases, but also other diseases as cancer and 
chronic lung diseases (10). It is needed to determine whether (current) over-treatment based on 
traditional risk factors could be diminished in the asymptomatic population with absent CAC. 
 
The ROBINSCA trial only performed a single screening round. The question is whether multiple 
CT scans might provide better individualized risk prediction. However, Radford and colleagues 
found that the progression in CAC score provides no additional prognostic information (35). 
Nevertheless, more research is needed to further understand the impact of CAC progression on 




Evidence for net-effectiveness of population-based screening for cardiovascular risk in an 
asymptomatic population will possibly enable large-scale implementation with large health gains. 
If a population screening programme for cardiovascular risk turns out to be successful, CAC 
screening is estimated to prevent 100,000 CHD-related death and 500.000 CHD-related hospital 
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Aims: Screening for a high cardiovascular disease (CVD) risk followed by preventive treatment 
can potentially reduce coronary heart disease (CHD)-related morbidity and mortality. 
ROBINSCA (Risk Or Benefit IN Screening for CArdiovascular disease) is a population-based 
randomized controlled screening trial that investigates the effectiveness of CVD screening in 
asymptomatic participants using the Systematic COronary Risk Evaluation (SCORE) model or 
Coronary Artery Calcium (CAC) scoring. This study describes the distributions in risk and 
treatment in the ROBINSCA trial. 
Methods and results: Individuals at expected elevated CVD risk were randomized  into 
screening arm A (n=14,478; SCORE, 10-year fatal and non-fatal risk); or screening arm B 
(n=14,450; CAC scoring). Preventive treatment was largely advised according to current Dutch 
guidelines. Risk and treatment differences between the screening arms were analysed. 12,185 
participants (84.2%) in arm A and 12,950 (89.6%) in arm B were screened. 48.7% were 
women, and median age was 62 (InterQuartile Range 10) years. SCORE screening identified 
45.1% at low risk (SCORE<10%), 26.5% at intermediate risk (SCORE 10-20%), and 28.4% at 
high risk (SCORE≥20%). According to CAC screening, 76.0% were at low risk 
(Agatston<100), 15.1% at high risk (Agatston 100-399), and 8.9% at very high risk 
(Agatston≥400). CAC scoring significantly reduced the number of individuals indicated for 
preventive treatment compared to SCORE (relative reduction women: 37.2%; men: 28.8%). 
Conclusion: We showed that compared to risk stratification based on SCORE, CAC scoring 
classified significantly fewer men and women at increased risk, and less preventive treatment 
was indicated.   




Cardiovascular disease (CVD) is the leading cause of death worldwide and it is responsible for 
45% of all annual deaths in Europe (1, 2). Although various preventive measures in terms of 
lifestyle and timely drug treatment are known to reduce CVD burden, their application is 
suboptimal and unhealthy lifestyles remain frequent. Population-based screening for 
cardiovascular risk aims to identify individuals at increased risk in order to stop or delay disease 
progression by preventive treatment. This might be an appropriate strategy to reduce CVD-
related events (3-5). However, there is no evidence from randomized controlled trials (RCT) on 
the effectiveness of screening and a reliable screening modality yet. 
 
One potentially suitable risk assessment tool is the Dutch Systematic Coronary Risk Evaluation 
(SCORE) risk model, which predicts 10-year risk for developing fatal and non-fatal CVD (4, 6, 
7). Although this model is easy to use and is integrated into current guidelines, it has limited 
accuracy in predicting the correct risk status. The indication for preventive treatment is often 
uncertain in intermediate-risk individuals, limiting the ability to prevent coronary heart disease 
(CHD) in this group (4, 8). Another potential screening modality is quantification of coronary 
artery calcification (CAC), expressed as CAC score, using computed tomography (CT) scanning 
(9, 10). Evidence shows that CAC scoring is a strong independent predictor of CHD events and 
improves classification of intermediate-risk individuals, causing a large shift in the distribution 
of CVD risk (11, 12). Currently, European and American guidelines recommend considering 
additional CAC scoring to guide preventive therapy decisions in intermediate-risk adults (4, 13). 
 
In CVD screening, the expected difference in CVD risk distribution between the SCORE model 
and CAC scoring might cause an effective shift towards more correctly classified individuals and 
more accurate risk reduction. Additionally, a reduction in preventive overtreatment with 
cardiovascular medication is expected when CAC scoring is used as the screening modality. This 
will not only be beneficial for participants as it reduces potential side effects, but it will also save 
costs (14). However, the effect of the shift in risk distribution in the setting of CVD screening 
in an elevated risk population is unknown. 
 
The Risk Or Benefit IN Screening for CArdiovascular diseases (ROBINSCA) trial is a 
population-based randomized controlled screening trial to investigate whether screening for a 
high risk of CVD in asymptomatic individuals followed by early treatment will reduce CHD-
related morbidity and mortality compared to no screening (15). The SCORE model and CAC 
scoring are used as potential screening modalities. The aim of the present study is to present the 
CVD risk distributions in both screening arms and to investigate the shift in risk distribution and 












The design, objectives and recruitment of the ROBINSCA trial have been described previously 
(15). In summary, 394,058 individuals, women aged 55-74 years and men aged 45-74 years from 
three regions in the Netherlands, were selected from the national population registry, and 
received an invitation to participate, including an information brochure, a baseline questionnaire, 
a waist circumference measuring tape and a written informed consent form. Asymptomatic 
individuals were subsequently selected based on at least one of the following inclusion criteria: 
1) a high self-measured waist circumference (≥88 cm for women and ≥102 cm for men); 2) a 
high body mass index (BMI; ≥30 kg/m2); 3) a family history of myocardial infarction or sudden 
death before the age of 65 years in first- or second-degree relatives; and/or 4) current smoking. 
Exclusion criteria were: 1) previously diagnosed CVD; 2) previous CVD surgery; 3) prescription 
of a combination of cholesterol- and blood pressure-lowering medication; 4) CAC score 
measurement in the past year; and/or 5) incomplete informed consent. In total, 43,447 eligible 
individuals were randomized (1:1:1) to either the control arm where usual care was continued, 
or to one of the two intervention arms where screening was offered. All participants received 
generic healthy lifestyle recommendations of the Dutch Heart Foundation (Figure 1). The 
current study focuses only on the screening arms. 
 
Screening 
Screening was performed from 2015 to 2018. In intervention arm A, the 10-year risk for fatal 
and non-fatal CVD was estimated using the adapted version of the SCORE model as described 
in the Dutch guideline for Cardiovascular Risk Management (CVRM, edition 2011) by the 
College of General Practitioners (7). Participants were invited for blood pressure and cholesterol 
measurement. The algorithm stratifies participants into low (SCORE <10%), intermediate 
(SCORE 10-20%) or high (SCORE ≥20%) risk according to the guideline (15). In intervention 
arm B, participants underwent CT scanning using a second-generation dual-source computed 
tomography system. The CAC imaging protocol has been described elsewhere (16). In short, 
images were analysed with semiautomatic identification of calcifications. A calcification was 
defined as an area with a density of ≥130 Hounsfield units and ≥2 adjacent voxels. Individual 
calcifications per coronary artery could be selected for CAC scoring using dedicated CAC scoring 
software. We calculated CAC scores according to Agatston (16, 17). CAC scores were stratified 
into low (Agatston <100), high (Agatston 100-399) and very high (Agatston ≥400) risk, 
according to cut-offs from literature (18). This terminology was chosen for the screening setting 
for early detection of preclinical disease. We used this classification in an asymptomatic 
population as an indication of preventive treatment and to distinguish between SCORE and 
CAC score. 
 
Study protocol for preventive treatment 
Participants were notified about their risk status, as were their general practitioners (GPs). 
Participants with a SCORE of ≥10% were advised to consult the GP. GPs are asked to initiate 
preventive treatment according to the Dutch CVRM guideline for ‘patients without CVD’ (7).  
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This guideline recommends lifestyle measures for all high-risk individuals (≥20%), and 
intermediate-risk individuals (≥10%) who have ≥1 risk-increasing factors. For these individuals, 
preventive drug treatment is recommended additionally when systolic blood pressure is  >140 
mmHg and/or LDL-cholesterol >2.5 mmol/L. The treatment advice for a high CAC score was 
designed in consultation with local cardiologists, GPs and the research team. The study advice 
recommended prescription of ACE-inhibitors and statins, independent from cholesterol and 
blood pressure levels (except when blood pressure is too low), for participants with a CAC score 
≥100, as adapted from the CVRM guideline for ‘patients with CVD’ (7).  
 
Statistical analysis  
Study population characteristics are expressed as percentages or medians (interquartile range; 
IQR) as appropriate for men and women separately. The Pearson’s chi-squared test and the 
Mann-Whitney U-test were used to analyse differences in distributions and medians respectively 
between intervention arm A and B. The distributions of CVD risk in both intervention arms 
were analysed using the Pearson’s chi-squared test and medians were analysed using the Kruskal-
Wallis test. The difference in preventive treatment indications between the intervention arms 
was analysed to check for potential reduction in overtreatment when using CAC scoring and was 
tested for statistically significant difference using the Pearson’s chi-squared test. The differences 
are presented as absolute and relative differences. A P value of < 0.005 was considered 
statistically significant after application of the Bonferroni correction. All analyses were 




Baseline characteristics  
In total, 14,478 and 14,450 participants were randomized into intervention arm A and 
intervention arm B, respectively. Screening attendance rate was high for both intervention arms; 
12,185 (84.2%) participants underwent a SCORE assessment and 12,950 (89.6%) participants 
underwent CT scanning for CAC quantification (p<0.001). Table A in the Supplementary data 
provides information on differences between screened and non-screened individuals. Baseline 
characteristics of the screened women and men of both intervention arms were comparable 
(Table 1). Median age of the women (12,232 out of 25,135; 48.7%) was 64.0 years (IQR 8) and 
of the men (12,903 out of 25,135; 51.3%) 59.0 years (IQR 13) (p<0.001). More men were current 
smokers (25.3 vs. 13.7%, p<0.001) and men had a higher BMI compared to women (26.9 vs. 
25.5 kg/m2; p<0.001). Reported family history of CHD was comparable for men and women 
(p=0.428). Slightly more women reported baseline use of antihypertensive treatment (21.9 vs. 
17.1%; p<0.001). 
 
SCORE and CAC score assessment  
Based on the Dutch SCORE model, 3,234 out of 6,009 (53.8%) women were classified as low-
risk, 1,479 (24.6%) as intermediate and 1,296 (21.6%) as high-risk. A significantly different CVD 
risk distribution was observed using CAC scoring: more low-risk women were identified. A zero 
CAC score was measured in 48.0% of the women (2,984/6,223). Further, 35.3% (2,196) had a  
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Table 1. Baseline characteristics of the study population split for women (a) and men (b).  
 Intervention arm A 
SCORE n/N (%) 
Intervention arm B 
CAC score n/N (%) 
P value 
a) Women  N=6,009 N=6,223  
Median age (IQR) 64.0 (8) 64.0 (8) 0.786 
Educational level† 
   Low 
   Medium 










Current smoker 827/6,009 (13.8) 850/6,223 (13.7) 0.868 
Median BMI (IQR) 25.5 (5.1) 25.5 (5.0) 0.826 
Median waist circumference* (IQR) 97.0 (13.5) 96.5 (13.5) 0.277 
Family history of CHD# 2,451/5,437 (45.1) 2,518/5,614 (44.9) 0.810 
Diabetes Mellitus 152/6,009 (2.5) 178/6,223 (2.9) 0.259 
Hypertension in past year 948/5,864 (16.2) 1,005/6,080 (16.5) 0.592 
Hypercholesterolemia in past year 938/5,802 (16.2) 974/5,994 (16.2) 0.903 
Baseline medical treatment    
   Antihypertensive 1,306/5,989 (21.8) 1,370/6,203 (22.1) 0.709 
   Lipid-lowering 449/5,987 (7.5) 490/6,189 (7.9) 0.388 
b) Men  N=6,176 N=6,727  
Median age (IQR) 59.0 (13) 59.0 (13) 0.095 
Educational level† 
   Low 
   Medium 










Current smoker 1,525/6,176 (24.7) 1,736/6,727 (25.8) 0.146 
Median BMI (IQR) 26.9 (4.3) 26.9 (4.4) 0.758 
Median waist circumference* (IQR) 104.5 (12.0) 104.5 (12.0) 0.647 
Family history of CHD# 2,637/5,718 (46.1) 2,812/6,262 (44.9) 0.183 
Diabetes Mellitus 200/6,176 (3.2) 258/6,727 (3.8) 0.067 
Hypertension in past year 964/6,020 (16.0) 1,119/6,561 (17.1) 0.116 
Hypercholesterolemia in past year 917/5,997 (15.3) 1,001/6,541 (15.3) 0.985 
Baseline medical treatment    
   Antihypertensive 1,017/6,157 (16.5) 1,187/6,710 (17.7) 0.078 
   Lipid-lowering 493/6,152 (8.0) 585/6,709 (8.7) 0.149 
A P value of < 0.005 was considered statistically significant after application of the Bonferroni correction. 
† Educational levels: low; primary, lower secondary general or lower vocational education, medium; intermediate 
vocational or higher secondary education, high; higher vocational education or university. 
* Waist circumference in centimetres.  
# Family history of myocardial infarction or sudden death before the age of 65 years in first and second degree relatives. 
CAC: coronary artery calcium; CHD: coronary heart disease; IQR; interquartile range: SCORE: systematic coronary risk 
evaluation 
 
low CAC score (Agatston 1-99), 12.1% (754) had a high CAC score (Agatston 100-399) and 
4.6% (289) had a very high CAC score (Agatston ≥400) (Table 2). Men were stratified into higher 
risk categories compared to women within both intervention arms. There were 2,262 out of 
6,176 (36.6%) men assessed as being at low risk based on the SCORE model, whereas 1,751 
(28.4%) and 2,163 (35.0%) were classified as intermediate and high-risk individuals respectively. 
Among the 6,727 men, 31.2% (2,098) had a zero CAC score. Furthermore, 2,561 (38.1%) men 
with a low CAC score were identified, followed by 1,200 (17.8%) and 868 (12.9%) with a high 













In both women and men, apart from the factors included in SCORE calculation, larger waist 
circumference, diabetes mellitus, and use of blood pressure or cholesterol lowering medication 
were associated with a higher SCORE. Additionally, a higher BMI was associated with a higher 
SCORE in women. In contrast, BMI and waist circumference were not associated with an 
increase in CAC score in women (p=0.653 and p=0.062, respectively). A higher BMI was not 
associated with a higher SCORE, nor with a higher CAC score in men (p=0.012 and p=0.605, 
respectively). Waist circumference and current smoking in men were not associated with an 
increase in CAC score (p=0.259 and p=0.811, respectively; Table 2 and 3).   
 
In addition to the SCORE calculations based on the Dutch CVRM guideline, Table B in the 
Supplementary data presents the converted SCORE risks according to the European model from 
the European Society of Cardiology (6). 
 
Difference in risk and preventive treatment 
The absolute reduction in the number of increased risk individuals was 29.4% in women and 
32.7% in men when CAC scoring was used as screening tool. The subsequent rate ratios (RR) 
were 0.363 (95% confidence interval (CI): 0.341-0.386) for women and 0.485 (95% CI: 0.466-
0.505) for men. This resulted in relative reductions of increased-risk individuals of 63.7% and 
51.5% in women and men respectively. 
 
 
Figure 2. Individuals indicated to consult their general practitioner for preventive drug treatment in intervention arm A 
and B based on estimated risks and the absolute and relative difference between both intervention arms.  
* Level of significance: p<0.001 
The difference in the number of individuals indicated for preventive treatment between the intervention arms were 
analysed and are presented as absolute and relative differences. 
CAC: coronary artery calcium; SCORE: systematic coronary risk evaluation 
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These large differences in CVD risk distributions between the screening modalities in both 
women and men caused statistically significant differences in the number of individuals indicated 
to consult their GP for preventive drug treatment (Figure 2). Potential preventive drug treatment 
was indicated for 1,604 out of 6,009 (26.7%) women according to the SCORE model, compared 
to 1,043 out of 6,223 (16.8%) women according to CAC scoring (p<0.001; absolute reduction 
of 9.9%). The relative reduction in the number of women indicated for preventive drug 
treatment was estimated to be 37.2% when using CAC scoring compared to SCORE calculation 
(based on RR 0.628, 95% CI: 0.586-0.673). Among men, 2,666 out of 6,176 (43.2%) were advised 
to start preventive drug treatment based on SCORE calculation, whereas 2,068 out of 6,727 
(30.7%) received preventive drug treatment advice based on CAC score (p<0.001; absolute 
reduction of 12.4%). Risk estimation using CAC scoring caused a relative reduction in the 





In this population-based screening RCT for the early detection and treatment of an increased 
risk for CVD, 25,135 asymptomatic participants were screened by means of either applying the 
SCORE model or CAC scoring. As expected, the CVD risk distributions differed significantly 
between the two screening modalities. Risk assessment through CAC scoring identified more 
low-risk individuals compared to the SCORE model. Follow-up analyses should establish 
whether the indicated high-risk individuals were treated correctly. 
 
The associations between traditional risk factors and a higher SCORE are a natural result of the 
SCORE model being based on these risk factors. However, similar associations were not 
observed in intervention arm B: higher CAC score categories were not associated with increasing 
waist circumference in women and men, nor with current smoking in men, nor with increasing 
BMI in women. In men, BMI was not associated with a higher SCORE, nor a higher CAC score. 
Regarding BMI, previous studies indeed reported that BMI does not predict CAC, which is 
largely related to the inability of BMI to differentiate between fat and muscle and the assumption 
that CAC scores can be underestimated in women with large chest size and large patients (19, 
20). In contrast, the lack of an association between waist circumference and CAC contradicts 
earlier findings indicating that waist circumference is associated with CAC beyond traditional 
risk factors (21). As there is no unambiguous evidence on this subject yet, future research should 
focus more on this potential association. Further, the proportion of male current smokers did 
not increase with higher CAC score categories. This is in line with previous research that 
concluded that the effect of current smoking on CAC might decrease with age (22). 
Discrepancies in presence of CAC and absence of traditional risk factors, and vice versa, might 
influence the decision on whether to start preventive drug treatment or not. In particular, current 
preventive treatment in people with zero CAC may be considered as overtreatment, since this 
score represents a minimal risk (23). Current preventive treatment decisions are largely based on 
traditional risk prediction models, whereas CAC scoring is thought to be better at correctly 




The SCORE model has several limitations, including the limited adaptation for different ethnic 
groups and age ranges, and the lack of incorporating risk modifiers that potentially reclassify 
CVD risk, such as socio-economic status, CVD family history and obesity, and therefore lacks 
discriminative power (4, 8). CAC scoring has superior discrimination and risk reclassification as 
compared with other risk indicators (25). Previous studies showed that asymptomatic 
intermediate-risk individuals were more often downgraded to a lower risk category after adding 
CAC scoring to risk prediction, which is in line with our results (11, 12). Additionally, the review 
of Greenland et al., which summarized the results of population-based cohorts, convincingly 
showed the value of CAC scoring as a single predictive cardiovascular risk marker beyond 
traditional risk factors (9). Furthermore, recent literature described that shared decision making 
guided by CAC scoring in intermediate-risk individuals can be a cost-effective strategy to avoid 
years of preventive medication (9, 14). Future analyses on CVD-related events in the 
ROBINSCA trial might add important evidence on the extent to which preventive treatment 
decisions should be based on CAC screening. 
 
The observed reduction in the number of individuals indicated to consult their GP for preventive 
treatment after screening by CAC scoring compared to screening using the SCORE model will 
potentially influence prevention strategies. However, future analyses on CVD-related events are 
needed to determine whether the indicated high-risk individuals were treated correctly. Within 
the screening setting of the current study, the results might imply a reduction in burden for both 
screening participants and GPs. The improved estimate of a CAC-based CVD risk status might 
reduce unnecessary stress that participants may experience upon receiving an unfavourable test 
result, while it might increase adherence to preventive treatment (26). For GPs, risk management 
in intervention arm B participants is less time consuming since the treatment indication in 
intervention arm A is not solely based on the SCORE model, but also on additional risk-
increasing factors that are not known in the ROBINSCA trial. Furthermore, a potential 
reduction in unnecessary treatment will reduce costs. However, as CT scanning is more 
expensive compared to using the SCORE model, the effectiveness of CT screening should first 
be confirmed (14, 27). 
 
The strength of this study is its large study population that was randomly selected from the 
national population registry. The aimed sample size was reached and therefore there should be 
sufficient power to show a reduction in CHD events of at least 15% (15). Furthermore, screening 
results were consistently obtained by adequately trained research personnel. A main limitation 
was that the presented data analysis is cross-sectional. Therefore, conclusions on the reduction 
of preventive overtreatment cannot be drawn yet. Future analyses on this subject are required. 
Another limitation was that recall bias might have caused some inaccuracies in the population 
characteristics data obtained from the self-reported baseline questionnaire. However, multiple 
questions were used per health topic to increase the reliability of the answers. Therefore, self-
reported questionnaires are the preferred and most cost-effective method for obtaining data in 
large study populations. Another point is that the described treatment indications in intervention 
arm A are not completely comparable with preventive treatment based on the SCORE model in 
current practice. To maintain feasibility, not all risk-increasing factors that co-determine the 
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treatment indication were incorporated in the screening as they are not part of the SCORE 
calculation itself. Lastly, the final decision regarding preventive treatment was made in 
consultation with the GP as GPs have access to participants’ medical background. The role of 
GPs in the risk management of increased-risk individuals is important in the feasibility of a 
potential CVD screening program. 
 
Within this first population-based RCT on screening for a high risk of CHD, CAC scoring 
classified significantly fewer individuals at intermediate and high-risk in both women and men 
compared to applying the SCORE model. Subsequently, the potential expected reduction in 
preventive overtreatment favours the use of CAC scoring in screening. However, future analyses 
are required to confirm the effectiveness of CVD screening for reduction of CHD and to 
incorporate costs of CT scanning and preventive treatment. Should screening for a high risk of 
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Cardiovascular disease (CVD) remains the main cause of death worldwide, accounting for 44% 
of all noncommunicable disease deaths, of which most are attributable to coronary heart disease 
(CHD) (1). Coronary artery calcification (CAC) has a strong association with major 
cardiovascular events and mortality, and has a high risk-predictive value of CHD in 
asymptomatic individuals (2, 3). It has been argued that the amount of CAC, expressed in the 
CAC score, can be used in population-based screening.  
The Dutch Risk Or Benefit IN Screening for CArdiovascular disease (ROBINSCA) trial is the 
first large-scale population-based randomized controlled trial (RCT) to investigate whether CAC 
screening followed by preventive treatment is effective in reducing CHD-related morbidity and 
mortality in asymptomatic individuals (4, 5). The aim of this study was to investigate the CAC 
prevalence and predictors in the ROBINSCA trial, which included an asymptomatic high-risk 
potential target population from the general population. 
 
The rationale and design of the ROBINSCA trial have been described before (5). Briefly, 43,447 
potential high-risk women (55-74 years) and men (45-74 years) from the national population 
registry who completed a baseline questionnaire to assess sociodemographic and health 
characteristics and gave informed consent were randomized (1:1:1) to either the control arm, 
intervention arm A (screening according to traditional risk factors) or intervention arm B (CAC 
screening). The current study focuses on the CAC screening arm (Figure 1). The Minister of 
Health authorized the ROBINSCA trial in 2013.  
CAC screening was performed using computed tomography scanning to identify CVD 
risk according to the CAC score, which represents the total amount of any CAC (6). CAC scores 
were categorized into low (Agatston 0-99), high (Agatston 100-399) and very high (Agatston 
≥400) risk (2).  
The effects of baseline characteristics on CAC score were analyzed using a two-step 
approach regression analyses for modeling presence, both any CAC and CAC score of 400 or 
higher (multivariable backward logistic regression), and extent (multivariable backward linear 
regression of the log-transformed CAC score) of CAC in women and men separately. Variables 
included in the models were age, educational level, waist circumference cut-off (88 cm for 
women and 102 cm for men), BMI cut-off (30 kg/m2), family history of CHD, smoking, diabetes 
mellitus, hypertension and/or hypercholesterolemia in the past year, and baseline use of either 
antihypertensive or lipid-lowering medication (according to self-reported data from baseline 
questionnaire). A P value of < 0.05 was considered statistically significant. All analyses were 
performed with IBM SPSS Statistics Version 24.0. 
 
Of the 12,950 screened participants, 48.1% were female and 94.2% were born in the 
Netherlands. Median age was 64 years in women and 62 years in men. Regarding CVD risk 
factors, 20.0% were current smokers at baseline, 3.4% reported diabetes mellitus, 16.4% and 
15.3% reported being diagnosed with respectively hypertension and hypercholesterolemia in 
the year before baseline, and 44.9% reported a family history of CHD. 
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Figure 1. Flowchart of the ROBINSCA trial study design in which CAC scoring is performed in intervention arm B. 
Abbreviations: BMI, Body Mass Index; CAC, Coronary Artery Calcium; CHD, Coronary Heart Disease; CT, Computed 






CAC was absent in 39.2% of the total study population. Overall, 48% of women had a 
zero CAC score compared to 20.7% of men in the same age category and 31.2% of all men. 
Further, 16.8% of women had a CAC score of 100 or higher compared to 40.0% of men in the 
same age category and 30.7% of all men. The CAC distribution in the ROBINSCA trial is 
compared to the German Heinz Nixdorf Recall Study and the American Multi Ethnic Study of 
Atherosclerosis in the Supplemental Material. 
Age, high waist circumference, family history of CHD, smoking at baseline, diabetes 
mellitus, self-reported hypertension or hypercholesterolemia at baseline, and baseline use of 
either antihypertensive or lipid-lowering medication were all selected as predictors in the 
backward regression analysis of the presence of CAC and CAC ≥ 400, and in the linear 
regression for predicting the log-transformed CAC extent in women (Table 1a). Age, educational 
level, high BMI, family history of CHD, smoking at baseline, diabetes mellitus, self-reported 
hypercholesterolemia at baseline, and baseline use of either antihypertensive or lipid-lowering 
medication were selected as predictors in the analyses for men (Table 1b). A higher educational 
level predicted a lower CAC score in men. The composition of the predictors differed 
moderately in the models for women and men. 
 
The associations of age, male sex, diabetes mellitus and smoking with higher CAC 
scores are well-known (7). A lower socioeconomic status, indicated by educational level, 
significantly predicted a higher extent of CAC in men. This association is possibly a result of a 
less favorable lifestyle in terms of smoking, diet and physical activity (8). Diabetes mellitus was 
one of the strongest predictors for CAC presence in women. This is in line with previous 
research where diabetes mellitus was identified to have a greater impact in women compared to 
men (9). Moreover, diabetes mellitus was a strong predictor for CAC extent in both sexes, 
suggesting that it is the most important risk factor for CAC development after sex and age. 
Regarding BMI and waist circumference, our results confirm earlier findings that BMI is not a 
strong predictor for presence of CAC, while waist circumference is more predictive of CAC 
presence (10). The predictive value of baseline use of either antihypertensive or lipid-lowering 
medication in CAC development was also seen in previous research. However, statins have been 
associated with increased CAC scores, but not with more CVD events. It is suggested that statins 
induce CAC progression and, at the same time, plaque repair (11).  
This study contributes to evidence on identifying the optimal target population for 
screening from the general population that will gain most healthy life-years from screening and 
subsequent treatment. All inclusion criteria for the ROBINSCA trial (smoking, waist 
circumference, BMI and a family history of CHD) were statistically significant predictors of 
CAC. Future analyses should provide evidence on whether the study population includes 
individuals who benefit most. 
A main limitation is that the ROBINSCA population is not representative of all ethnic 
groups as a result of a homogeneous distribution, though ethnicity is known to affect CAC 
prevalence and severity. Another possible limitation is that study participants tend to be generally 
healthier than similar individuals not responding to the participation invitation (healthy volunteer 
effect). However, the inclusion- and exclusion criteria should have minimized this effect. 
Furthermore, participants using both cholesterol-lowering and antihypertensive medication were 
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excluded from the trial, which might have affected the found associations of CAC with CVD 
medication. Finally, baseline data was obtained using a self-reported questionnaire, rather than 
diagnostic test measures, and might entail some inaccuracies. 
In conclusion, this currently largest population-based RCT for CAC screening in 
asymptomatic middle-aged Caucasian individuals showed that 30.7% of men and 16.8% of 
women with a CAC score of ≥100 urgently require preventive treatment. To a large extent, male 
sex and increasing age, followed by diabetes mellitus and smoking, influence CAC distribution. 
These results can therefore help determine the best risk prediction and prevention strategy 












































































































































































































































































































































































































The authors would like to thank the European Union for funding the ROBINSCA trial and the 
Ministry of Health, Welfare and Sports for the ethical approval to perform the trial. Naturally, 
we thank all participants for their participation. Furthermore, we would like to thank M. Quak 
for the extensive research assistance, RADventure for developing the data management system 
and IVA group for handling all questionnaires and letters. Lastly, we thank all employees of the 
radiology departments of the screening centers (Gelre Hospital Apeldoorn, Bronovo Hospital 
The Hague and University Medical Centre Groningen) for scanning participants. 




1. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et 
al. European Cardiovascular Disease Statistics 2017. European Heart Network, 
Brussels. 2017. 
2. Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and 
Cardiovascular Risk. J Am Coll Cardiol. 2018 Jul 24;72(4):434-47. 
3. Budoff MJ, Young R, Burke G, Jeffrey Carr J, Detrano RC, Folsom AR, et al. Ten-year 
association of coronary artery calcium with atherosclerotic cardiovascular disease 
(ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J. 2018 
Jul 1;39(25):2401-8. 
4. McEvoy JW, Martin SS, Blaha MJ, Polonsky TS, Nasir K, Kaul S, et al. The Case For 
and Against a Coronary Artery Calcium Trial: Means, Motive, and Opportunity. JACC 
Cardiovasc Imaging. 2016 Aug;9(8):994-1002. 
5. Van der Aalst CM, Vonder M, Gratama JM, Adriaansen HJ, Kuijpers D, Denissen 
SJAM, et al. Risk or Benefit in Screening for Cardiovascular Disease (ROBINSCA): 
The Rationale and Study Design of a Population-Based Randomized-Controlled 
Screening Trial for Cardiovascular Disease. J Clin Trials. 2019;9(1). 
6. Vonder M, van der Aalst CM, Vliegenthart R, van Ooijen PMA, Kuijpers D, Gratama 
JW, et al. Coronary Artery Calcium Imaging in the ROBINSCA Trial: Rationale, 
Design, and Technical Background. Acad Radiol. 2018 Jan;25(1):118-28. 
7. Pletcher MJ, Sibley CT, Pignone M, Vittinghoff E, Greenland P. Interpretation of the 
coronary artery calcium score in combination with conventional cardiovascular risk 
factors: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2013 Sep 
3;128(10):1076-84. 
8. Djekic D, Angeras O, Lappas G, Fagman E, Fagerberg B, Bergstrom G, et al. Impact 
of socioeconomic status on coronary artery calcification. Eur J Prev Cardiol. 2018 
Nov;25(16):1756-64. 
9. Nicoll R, Wiklund U, Zhao Y, Diederichsen A, Mickley H, Ovrehus K, et al. Gender 
and age effects on risk factor-based prediction of coronary artery calcium in 
symptomatic patients: A Euro-CCAD study. Atherosclerosis. 2016 Sep;252:32-9. 
10. Roy SK, Zeb I, Kadakia J, Li D, Budoff MJ. Body surface area is a predictor of coronary 
artery calcium, whereas body mass index is not. Coron Artery Dis. 2012 Mar;23(2):113-
7. 
11. Henein M, Granasen G, Wiklund U, Schmermund A, Guerci A, Erbel R, et al. High 
dose and long-term statin therapy accelerate coronary artery calcification. Int J Cardiol. 





SUPPLEMENTAL MATERIAL  
 
The coronary artery calcification (CAC) distribution in the ROBINSCA trial can be compared 
to other large studies like the American Multi Ethnic Study of Atherosclerosis (MESA) and the 
German Heinz Nixdorf Recall Study (HNR) (1). The Pearson’s Chi-squared test was used to 
compare CAC score 0 vs. >0 distributions in the ROBINSCA trial, MESA and HNR. To match 
for age and ethnicity, a subset of Caucasians of the total MESA population was used (data not 
shown, adapted from Erbel et al.(1)). The ROBINSCA population included slightly fewer 
individuals with diagnosed diabetes mellitus based on self-report. The distributions of absolute 
CAC scores for women and men in the MESA (n=2,220), HNR (n=3,126) and the ROBINSCA 
trial followed the same trend (Figure 1). However, overall differences in the presence of CAC 
were statistically significant between ROBINSCA and both MESA and HNR (p<0.001). Zero 
CAC scores were most prevalent in MESA (47.5%) followed by ROBINSCA (39.2%) and then 
HNR (33.0%). Regarding sex-specific distributions, presence of CAC was comparable between 
ROBINSCA and HNR in women (respectively 52.0 vs. 53.8%; p=0.206) and CAC presence in 
men was comparable between ROBINSCA and MESA (68.8 vs. 67.6%; p=0.423).  
 
Comment  
We compared CAC distribution in the ROBINSCA trial to those in the Caucasian individuals of 
the MESA and HNR asymptomatic populations (1). An important population selection 
difference was the age of women; the ROBINSCA trial included women aged 55-74 years, 
whereas MESA and HNR included women aged 45-75 years. Furthermore, the exclusion criteria 
of MESA and HNR were slightly more selective in terms of excluding among others individuals 
with medical conditions preventing follow-up, with active cancer treatment and living in a 
nursing home. On the other hand, individuals using both cholesterol- and blood pressure-
lowering medication were excluded in the ROBINSCA trial. The MESA population had the best 
CVD risk factor profiles (e.g. lowest number of current smokers). However, among this 
population were the most antihypertensive and lipid-lowering medication users, which is 
potentially a result from a high prevalence of hypertension and hypercholesterolemia. The same 
CAC distribution pattern was seen; however, overall differences in CAC presence were 
statistically significant. This is probably related to a different prevalence of risk factors, since 
MESA had the healthiest population which can possibly be a result of excluding individuals with 
any serious medical condition that would prevent long-term participation. Another important 
explanation is the discrepancy in the age range of the women, since MESA and HNR included 
also younger women. Regarding the women-specific comparison, the ROBINSCA distribution 
would presumably approach the MESA distribution if the same age categories were included. In 
contrast, a comparison was possible for men and a difference in CAC presence was seen between 
ROBINSCA and HNR. In the HNR study, CAC scores were higher, possibly as a result of less 
favorable risk factor levels (1).  
 




Figure 1. Comparison of distributions of absolute coronary calcium scores in the Risk Or Benefit IN Screening for 
CArdiovascular disease (ROBINSCA) trial, the Multi-Ethnic Study of Atherosclerosis (MESA) and the Heinz Nixdorf 
Recall (HNR) study.  
Data on CAC scores in MESA and HNR from Erbel, et al (1). 
* Different age categories for women: ROBINSCA; 55-77 years, MESA and HNR; 45-75 years.  
Abbreviations: CAC = Coronary Artery Calcium, HNR = Heinz Nixdorf Recall study, MESA = Multi-Ethnic Study of 
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Objectives: Presence of coronary artery calcium (CAC) is a strong predictor of coronary heart 
disease (CHD). The Dutch population-based randomized-controlled Risk Or Benefit IN 
Screening for CArdiovascular disease (ROBINSCA) trial incorporates CAC quantification as 
screening modality to identify individuals at high cardiovascular disease (CVD) risk. This study 
presents CAC prevalence and its predictors in the ROBINSCA screening trial. 
Methods: Asymptomatic individuals with an increased risk (n=14,450) were selected from the 
general population. CAC scores were measured using computed tomography scanning in 12,950 
(89.6%) men (aged 45-74 years) and women (aged 55-74 years, 48.1%) (median age 62 years). 
Absolute distributions by baseline characteristics were calculated and a two-step regression 
approach was used to identify relevant predictors. 
Results: CAC was absent in 48% of the women compared to 31.2% of men and CAC score was 
≥100 (Agatston) in respectively 16.8% and 30.7%. Men had substantially higher median CAC 
scores, respectively 1 and 17. Logistic regression results indicated that age, diabetes mellitus and 
smoking were the strongest predictors for CAC presence in women, and age, antihypertensive 
and lipid-lowering medication use in men. In the linear model for predicting the extent of CAC, 
age was the strongest predictor for both women and men, followed by smoking for women and 
lipid-lowering medication use for men.  
Conclusion: This is currently the largest population-based CAC screening study in 
asymptomatic middle-aged individuals, showing that 30.7% of men and 16.8% of women from 
the general population with a CAC score of ≥100 are recommended for preventive treatment. 
 
  




Cardiovascular disease (CVD) remains the main cause of death worldwide, accounting for 44% 
of all noncommunicable disease deaths, of which most are attributable to coronary heart disease 
(CHD) (1-3). Coronary artery calcification (CAC) has a strong association with major 
cardiovascular events and CHD-related and all-cause mortality (4, 5). The CHD risk-predictive 
value of presence of CAC is high in asymptomatic individuals, independent from the traditional 
risk factors including age, male sex, smoking, hypertension, hypercholesterolemia, and diabetes 
mellitus (4, 6, 7). It has been argued that the amount of CAC, expressed in the CAC score, can 
be used in population-based screening. However, there is not yet solid evidence from 
randomized controlled trials (RCT) that population-based CAC screening followed by 
preventive treatment is effective in reducing CVD-related morbidity and mortality (8, 9).  
 
The Dutch Risk Or Benefit IN Screening for CArdiovascular disease (ROBINSCA) trial is the 
first large-scale population-based screening RCT. It included 43,447 asymptomatic individuals 
to investigate whether screening for CVD risk followed by subsequent risk reducing treatment 
can reduce CHD-related morbidity and mortality by at least 15% compared to no screening (10). 
Individuals with an expected increased CVD risk, based on a questionnaire and measured waist 
circumference, were selected for participation. Screening is carried out by CAC quantification 
using computed tomography (CT) scanning (10).  
 
Some smaller prospective studies have investigated CAC prevalence in different sexes, age 
categories, socioeconomic status (educational level) categories and ethnicities (11, 12). However, 
the ROBINSCA trial provides detailed information on CAC prevalence, distribution and 
predictors in the general high-risk population. Moreover, the sample size allows for explicit 
examination of predictors of high CAC scores (≥400). The ROBINSCA trial is sufficiently 
powered to show whether screening will reduce CHD-related morbidity and mortality, but the 
trial needs longer follow-up. The results will contribute to evidence of the highest level on 
selecting those individuals who are expected to benefit most from screening and subsequent 
treatment. RCTs such as the ROBINSCA trial are essential to optimize guidelines and policy 
regarding CAC screening. 
 
The aim of this study was to investigate the CAC prevalence and predictors in the large 
ROBINSCA trial, which included an asymptomatic high-risk potential target population for 




The data that support the findings of this study are available from the corresponding author 
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Study population 
The rationale and design of the ROBINSCA trial have been described before (10). In brief, 
394,058 women (55-74 years) and men (45-74 years) from the national population registry 
received an information brochure, a waist circumference measurement tape, a baseline 
questionnaire to assess sociodemographic and (CVD-related) health characteristics and a form 
to obtain written informed consent. Asymptomatic respondents free of diagnosed CVD were 
found eligible for participation when a potentially increased CVD risk was observed based on 
traditional CVD risk factors. All eligible respondents who gave informed consent were 
randomized (1:1:1) to either the control arm, intervention arm A (screening according to the 
Systematic Coronary Risk Evaluation (SCORE) model) or intervention arm B (CAC screening). 
Five year follow-up is required to investigate the effect of screening on CHD events compared 
to the control arm (Figure 1). The current study focuses on the CAC screening arm. The Minister 
of Health, Welfare and Sports authorized the ROBINSCA trial after positive advice from the 
Dutch Health Council in 2013. 
 
CAC quantification and preventive treatment 
The design and technical background of the CAC imaging protocol have been described 
elsewhere (13). A second-generation dual-source CT system was used to identify CVD risk 
according to the CAC score, which represents the total amount of any CAC (SOMATOM Flash, 
Siemens Healthineers, Erlangen, Germany). Prospective ECG triggering was used to acquire 
images at 60% of the inter-beat interval during an inspiratory breath-hold. Experienced 
technicians performed the scans and were blinded from clinical data of the participants. Images 
were reconstructed with a slice thickness of 3.0 mm by default and analyzed with semiautomatic 
selection of calcifications per coronary artery using dedicated CAC scoring software (CaSc, 
Syngo.via, Siemens, Erlangen, Germany). A calcification was defined as an area with a density of 
≥130 Hounsfield units and ≥2 adjacent voxels, resulting in a CAC score according to Agatston 
(14). CAC scores were categorized into low (Agatston 0-99), high (Agatston 100-399) and very 
high (Agatston ≥400) risk (4). The result was communicated to both participants and their 
general practitioners (GP) along with preventive treatment advice for (very) high-risk individuals. 
The advice for CAC scores of ≥100 consisted of prescription of ACE inhibitors and statins, 
which is in accordance with the Dutch guideline for Cardiovascular Risk Management (CVRM) 
for “patients with CVD” of the Dutch College of General Practitioners (15). This specific advice 
was formulated based on recent literature and in consultation with the researchers and local 
cardiologists and GPs.  
 
Statistical analysis 
Study population characteristics are shown as frequencies or medians (interquartile range; IQR) 
for skewed variables. Baseline variables are evaluated for statistically significant differences using 
Pearson’s Chi-squared test or the Mann-Whitney U-test, as appropriate. Differences between 
CAC distributions by age category, educational level, smoking status, diabetes mellitus status, 
and self-reported hypertension and hypercholesterolemia in the past year were tested using 
Pearson’s Chi-squared test. Percentiles of CAC scores were calculated for the total study 
population and for age categories for both women and men. The effects of baseline 
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Figure 1. Flowchart of the ROBINSCA trial study design in which CAC scoring is performed in intervention arm B. 
Abbreviations: BMI, Body Mass Index; CAC, Coronary Artery Calcium; CHD, Coronary Heart Disease; CT, Computed 
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characteristics on CAC score were analyzed using regression analyses for women and men 
separately. Since the CAC score distribution is heavily right skewed, we used a two-step approach 
for modeling both presence and extent of CAC. Presence of CAC (CAC score 0 vs. >0) was 
predicted using multivariable backward logistic regression, and the extent of CAC was predicted 
using multivariable backward linear regression of the log-transformed CAC score >2 (since log-
transformed CAC score >0 did not approach normal distribution). Variables included in the 
models were age, educational level, waist circumference cut-off (88 cm for women and 102 cm 
for men), BMI cut-off (30 kg/m2), family history of CHD, smoking, diabetes mellitus, 
hypertension in the past year, hypercholesterolemia in the past year, baseline use of 
antihypertensive medication and baseline use of lipid-lowering medication (all according to self-
reported data from baseline questionnaire). The same variables were included in a multivariable 
backward logistic regression model to predict a CAC score of 400 or higher. A P value of < 0.05 





Study population  
In total, 14,450 individuals were randomized to CAC scoring. Screening attendance was 89.6% 
(12,950) and was comparable for men and women, respectively 89.9% and 89.3% (p=0.159). 
Non-screened participants were more often smokers (27.3% vs 20%), lower educated (45.9% 
vs. 36.9%) and median age was one year higher. Sex, CHD family history, diabetes mellitus, and 
hypertension and hypercholesterolemia in the year before baseline were comparable for screened 
and non-screened participants. Of the screened participants, 48.1% were female and 94.2% were 
born in the Netherlands. Median age at CAC quantification was 64 (IQR 8) years in women and 
62 (IQR 13) years in men. Regarding CVD risk factors, 20.0% were current smokers at baseline, 
3.4% reported diabetes mellitus, 16.4% and 15.3% reported being diagnosed with respectively 
hypertension and hypercholesterolemia in the year before baseline, and 44.9% reported a family 
history of myocardial infarction or sudden death before the age of 65 years in first and second 
degree relatives (Table 1).  
 
CAC distribution 
CAC was absent in 39.2% of the total study population. Furthermore, 36.7% had a CAC score 
between 1 and 99, 15.1% between 100 and 399, and 8.9% had a CAC score of 400 or higher. 
Overall, 48% of women had a zero CAC score compared to 20.7% of men in the same age 
category and 31.2% of all men. Further, 16.8% of women had a CAC score of 100 or higher 
compared to 40.0% of men in the same age category and 30.7% of all men (Table 1). Statistically 
significant higher CAC scores were observed with higher age, lower educational level, current 
smoking, having diabetes, and hypertension and hypercholesterolemia in the past year (Figure 
2). The specific CAC score percentiles in Table 2 accentuate the wide variations of CAC among 
sexes and age categories; in particular, CAC development seems to differ approximately by ten 
years and therefore possibly progresses slower in women. The CAC distribution in the  
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Table 2. Coronary artery calcium score percentiles estimated by sex and age.   
 Total  Women 
 
   Men 
 
  





















25th  0 0 n/a 0 0  0 0 0 16 
50th  6 1  0 9  17 0 20 124 
75th  92 48  23 87  156 21 136 424 
90th  356 200  115 303  530 122 468 1,034 
95th  691 379  230 567  966 240 801 1,568 
Abbreviations: CACS, Coronary Artery Calcium Score; y, years 
n/a: women aged 45-54 years old are not part of the ROBINSCA study population 
 
ROBINSCA trial is compared to the American Multi Ethnic Study of Atherosclerosis (MESA) 
and the German Heinz Nixdorf Recall Study (HNR) in the Supplemental Material. 
 
Predictors for CAC presence and extent 
Backward regression analysis of the presence of CAC in women included age, high waist 
circumference, family history of CHD, baseline smoking, diabetes mellitus, self-reported 
hypertension, self-reported hypercholesterolemia (not statistically significant; p=0.097), and 
baseline use of either antihypertensive or lipid-lowering medication as predictors in the model 
(Table 3a). This model had an area under the curve (AUC; model indicator for discrimination 
between CAC score 0 vs. >1) of 0.685. Highest odds ratios were found for age per 10 years 
(2.74; confidence interval (CI) 2.46-3.05; p<0.001), diabetes mellitus (2.26; 95% CI 1.51-3.39; 
p<0.001) and smoking at baseline (2.00; 95% CI 1.69-2.37; p<0.001). The linear regression for 
predicting the log-transformed CAC extent selected age, family history of CHD, smoking, 
diabetes mellitus, and baseline use of either antihypertensive or lipid-lowering medication. The 
explanation of variation, by means of the adjusted R-square, was 0.043. Extent of CAC was 
predominantly predicted by age (coefficient 0.48; 95% CI 0.36-0.59; p<0.001) and smoking 
(coefficient 0.35; 95% CI 0.19-0.51; p<0.001) (Table 3a). For men, the backward logistic 
regression analysis for presence of CAC selected age, family history of CHD, smoking, self-
reported hypercholesterolemia (not statistically significant; p=0.063), and baseline use of either 
antihypertensive or lipid-lowering medication as predictors in the model (AUC: 0.686). Age had 
the highest odds ratio (2.97; 95% CI 2.52-3.46; p<0.001), followed by antihypertensive 
medication (1.94; 95% CI 1.55-2.43; p<0.001) and lipid-lowering medication (1.48; 95% CI 1.10-
2.00; p=0.011) (Table 3b). The linear regression analysis included age, educational level, BMI, 
family history of CHD, smoking, diabetes mellitus, and baseline use of either antihypertensive 
or lipid-lowering medication (adjusted R-square: 0.077). Again, age had the highest coefficient 
(0.70; 95% CI 0.60-0.80; p<0.001), followed by lipid-lowering medication (0.40; 95% CI 0.21-
0.58; p<0.001). 
 
A CAC score of 400 or higher was predicted by age, use of lipid-lowering medication, smoking, 
use of antihypertensive medication and family history of CHD (from highest to lowest odds 
ratio) in women according to logistic regression analysis (AUC: 0.744). Age had also the highest 
odds ratio in the logistic regression model for men, followed by family history of CHD, smoking, 
use of lipid-lowering medication, use of antihypertensive medication, diabetes mellitus (not  
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Table 3. Baseline predictors for the presence and extent of coronary artery calcium.   
 Logistic regression for CAC 
presence (CAC score = 0 vs. >0) 
 Linear regression for log-
transformed CAC extent a 
 Odds ratio 
(95% CI) 
P value  Coefficient 
(95% CI) 
P value 
a) Women      
Age, per 10 years 2.74 (2.46-3.05) <0.001***  0.48 (0.36-0.59) <0.001*** 
Waist circumference cut-off b 1.22 (1.03-1.46) 0.024*    
Family history of CHD c 1.63 (1.45-1.84) <0.001***  0.20 (0.08-0.31) 0.001** 
Smoker at baseline 2.00 (1.69-2.37) <0.001***  0.35 (0.19-0.51) <0.001*** 
Diabetes mellitus 2.26 (1.51-3.39) <0.001***  0.33 (0.04-0.63) 0.026* 
Hypertension in past year (self-
reported) 
1.27 (1.06-1.51) 0.008**    
Hypercholesterolemia in past year (self-
reported) 
1.15 (0.98-1.36) 0.097    
Antihypertensive medication 1.28 (1.09-1.49) 0.002**  0.28 (0.14-0.42) <0.001*** 
Lipid-lowering medication 1.81 (1.41-2.32) <0.001***  0.22 (0.02-0.42) 0.033* 
 Area under the curve: 0.685  Adjusted R2: 0.043 
b) Men    
Age, per 10 years 2.97 (2.52-3.46) <0.001***  0.70 (0.60-0.80) <0.001*** 
Educational level d 
   Low  
   Medium 
   High 
    
 
-0.15 (-0.30- -0.002) 





Body Mass Index cut-off e    0.23 (0.07-0.38) 0.004** 
Family history of CHD c 1.38 (1.18-1.62) <0.001***  0.27 (0.15-0.38) <0.001*** 
Smoker at baseline 1.35 (1.12-1.64) 0.002**  0.30 (0.16-0.44) <0.001*** 
Diabetes mellitus    0.39 (0.13-0.66) 0.004** 
Hypercholesterolemia in past year (self-
reported) 
1.25 (0.99-1.59) 0.063    
Antihypertensive medication 1.94 (1.55-2.43) <0.001***  0.32 (0.18-0.46) <0.001*** 
Lipid-lowering medication 1.48 (1.10-2.00) 0.011*  0.40 (0.21-0.58) <0.001*** 
 Area under the curve: 0.686  Adjusted R2: 0.077 
Abbreviations: CAC, Coronary Artery Calcium; CHD, Coronary Heart Disease; CI, Confidence Interval 
a Log-transformation in individuals with CAC score > 2 because transforming CAC score > 0 did not result in a normal 
distribution. 
b Trial inclusion criteria cut-off for waist circumference: ≥88 cm for women and ≥102 cm for men. 
c Family history of myocardial infarction or sudden death before the age of 65 years in first and second degree relatives. 
d Educational levels: low; primary, lower secondary general or lower vocational education, medium; intermediate 
vocational or higher secondary education, high; higher vocational education or university. 
e Trial inclusion criteria cut-off for Body Mass Index: ≥30 kg/m2. 
*P<0.05, **P<0.01, ***P<0.001. 
 
statistically significant; p=0.085) and BMI (AUC: 0.698). A high educational level was selected 
as significant predictor for a CAC score lower than 400 (odds ratio 0.77; 95% CI 0.63-0.93; 
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Table 4. Logistic regression analysis of baseline predictors for a coronary artery calcium score of 400 or higher.   
 Women  Men 
 Odds ratio 
(95% CI) 
P value  Odds ratio 
(95% CI) 
P value 
Age, per 10 years 3.58 (2.79-4.64) <0.001***  3.02 (2.57-3.52) <0.001*** 
Educational level a 
   Low  
   Medium 
   High 








Body Mass Index cut-off b    1.33 (1.07-1.66) 0.011* 
Family history of CHD c 1.70 (1.31-2.21) <0.001***  1.57 (1.32-1.87) <0.001*** 
Smoker at baseline 2.18 (1.55-3.05) <0.001***  1.52 (1.24-1.86) <0.001*** 
Diabetes mellitus    1.39 (0.96-2.03) 0.085 
Antihypertensive medication 1.93 (1.46-2.57) <0.001***  1.47 (1.21-1.79) <0.001*** 
Lipid-lowering medication 2.25 (1.54-3.30) <0.001***  1.49 (1.14-1.95) 0.004** 
 Area under the curve: 0.744  Area under the curve: 0.698 
Abbreviations: CHD, Coronary Heart Disease; CI, Confidence Interval 
a Educational levels: low; primary, lower secondary general or lower vocational education, medium; intermediate 
vocational or higher secondary education, high; higher vocational education or university. 
b Trial inclusion criteria cut-off for waist circumference: ≥88 cm for women and ≥102 cm for men. 
c Family history of myocardial infarction or sudden death before the age of 65 years in first and second degree relatives. 




This large-scale population-based study investigated the prevalence and extent of CAC, and 
identified predictive baseline characteristics in an asymptomatic Dutch population that is part of 
the ROBINSCA trial. This trial aims to investigate whether CAC screening is effective in 
reducing CHD-related morbidity and mortality in a high-risk population. This study contributes 
to evidence on identifying the optimal target population for screening that will gain most healthy 
life-years from screening and subsequent treatment. 
 
The well-known effect of age and male sex causing higher CAC scores is also seen in the 
ROBINSCA trial (11, 16). Furthermore, socioeconomic status, indicated by educational level, 
was related to CAC and significantly predicted the extent of CAC in men. Our results support 
the limited existing evidence that a lower educational level is related to an increased CAC (17, 
18). This is possibly a result of a less favorable lifestyle in terms of smoking, diet and physical 
activity (19).  
 
CAC score percentiles in the ROBINSCA trial emphasize the substantial differences in extent 
of coronary calcification between asymptomatic men and women in the same age groups. 
Notably, our results showed that the CAC score percentiles of women aged 55-64 years were 
similar to men of one age category younger (45-54 years). This outcome was even more profound 
at higher ages; women of the highest age category (65-77 years) had considerably lower CAC 
scores compared to men of a younger age category, possibly indicating an accelerated 
progression of CAC in men. A recent study showed that men have a higher net reclassification 
index from CAC scoring and thus benefit more from adding CAC to risk assessment compared 
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to women (20). Therefore, it seems appropriate to select women for CVD screening at 
approximately ten years higher age compared to men. However, another study found no 
differences in reclassification between men and women, and there are some female-specific risk 
factors that substantially increase CVD risk, including preeclampsia and menopause onset (7, 
21). Future research should focus more on CVD risk assessment strategies in women with these 
risk factors. Although CAC score percentile ranks are described to be less capable in risk 
stratification than sex- and age-specific absolute scores, they can be useful to assess the level of 
CVD risk relative to other persons with the same age and sex (22).  
 
The investigated predictive value of several cardiovascular risk factors was similar to previous 
studies. Diabetes mellitus was one of the strongest predictors for CAC presence in women. This 
is in line with previous research where diabetes mellitus was identified to have a greater impact 
in women compared to men (23). Moreover, diabetes mellitus was a strong predictor for CAC 
extent in both sexes. This confirms the idea that diabetes mellitus is the most important risk 
factor for CAC development after sex and age (24). The results are also consistent with those of 
Kronwal et al. and Pletcher et al. who showed that diabetes mellitus is a major risk factor for 
CAC in MESA participants (16, 25). Another important risk 
 
factor in the development of CAC is smoking behavior, as current smoking predicted both the 
presence and the extent of CAC in women and men. The smoking prevalence is higher among 
men, however, the reduction of smoking prevalence declined more slowly among women over 
the past decades and prolonged smoking is more harmful for women regarding CVD outcomes 
(21, 26). The regression analyses showed that a high waist circumference predicted CAC 
presence in women, but not the extent of CAC. This partly contradicts previous research that 
described a high waist circumference as a risk factor for CAC accumulation (27). Regarding BMI, 
no predictive value was observed in women and it only predicted the extent of CAC in men. 
These results confirm earlier findings that showed that BMI is not a strong predictor for presence 
of CAC, and that waist circumference is more predictive of CAC (28, 29). 
 
Baseline use of either antihypertensive or lipid-lowering medication were other predictive 
variables selected by the regression models. In contrast, self-reported hypertension and 
hypercholesterolemia were less or not predictive of calcifications. However, these variables are 
likely to have some overlap, as individuals using antihypertensive or lipid-lowering medication 
probably faced elevated levels of blood pressure or cholesterol in earlier years. In previous 
research, statins have been associated with increased CAC scores, but not with more CVD 
events. It is suggested that statins induce CAC progression and, at the same time, plaque repair 
(30). Largely the same baseline variables also significantly predicted CAC scores of 400 or higher. 
Interestingly, diabetes mellitus was not selected in the female-specific model and not statistically 
significant in the analysis for men, contradicting previous research (24). However, another study 
showed that age, male sex, smoking, hypertension and hypercholesterolemia were all predictive 
of a CAC score of 400 or higher, and not diabetes mellitus (31).  
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With respect to the target population for CVD screening, it is important to select the optimal 
population that includes individuals who gain the most healthy life-years from screening and 
subsequent treatment. All inclusion criteria for the ROBINSCA trial (smoking, waist 
circumference, BMI and a family history of CHD) were statistically significant predictors of the 
presence of CAC. Furthermore, the extent of calcifications was predicted by a family history of 
CHD and smoking. Overall, it seems that a large proportion of the targeted high-risk population 
can be identified from the general population using these inclusion criteria. Future analyses of 
morbidity and mortality will provide more evidence on the (cost-) effectiveness of CVD 
screening in the ROBINSCA trial.  
 
A strength of this study is its population-based selection of asymptomatic individuals from the 
national population registry. Through this approach, many individuals were reached and selected 
for participation. Furthermore, all CT-scans were analyzed in one analyzing center expert in CAC 
scoring, allowing for consistent review of CAC. However, the generalizability of our results is 
subject to certain limitations. For instance, the ROBINSCA population is not representative of 
all ethnic groups. The study population consisted mainly of native Dutch individuals (94%), 
whereas 18% of the general population within the same age range in the Netherlands have a 
migration background (32). As a result of this homogeneous distribution, ethnicity could not be 
included in the regression analyses, even though ethnicity is known to affect prevalence and 
severity of CAC. Another possible limitation is that study participants tend to be generally 
healthier than similar individuals not responding to the participation invitation (healthy volunteer 
effect). Participants were however selected on having at least one risk factor for developing CVD 
and the use of our inclusion- and exclusion criteria should have minimized this effect. Finally, 
baseline data was obtained using a self-reported questionnaire including a self-measurement of 
waist circumference, rather than diagnostic test measures, and might entail some inaccuracies. 
However, self-reported questionnaires remain the preferred method for obtaining data from an 
extensive population as in the ROBINSCA trial, where 394,058 individuals were approached and 
invited to participate.  
 
This study summarizes CAC prevalence in a large sample of asymptomatic individuals derived 
from the general ‘at risk’ Caucasian population. To a large extent, male sex and increasing age, 
followed by diabetes mellitus and smoking, influence CAC distribution. This is currently the 
largest population-based CAC screening study in asymptomatic middle-aged men and women. 
It shows that 30.7% of men and 16.8% of women with a CAC score of ≥100 are recommended 
for preventive treatment. These results can therefore help determine the best risk prediction and 
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Introduction: A teachable moment for preventive behavioural change can occur when 
asymptomatic individuals receive their cardiovascular disease screening result. This study 
investigated prevention-seeking behaviour and compliance with preventive treatment of 
participants of the population-based Risk Or Benefit IN Screening for CArdiovascular disease 
(ROBINSCA) trial after receiving a screening result. 
Methods: Asymptomatic Dutch individuals (n = 43,447) were randomly assigned (1:1:1) to 
screening for cardiovascular disease by either traditional risk assessment (intervention arm A), 
or determining the amount of coronary artery calcification (intervention arm B), or to usual care 
(control arm). A random sample (n = 600) of ROBINSCA participants with a screening result 
(arms A and B) received an online questionnaire (in 2017) to measure the impact of a 
cardiovascular disease screening result in low and increased (arm A: risk > 10%; arm B: 
Agatston ≥ 100) risk groups. 
Results: Of all respondents (438/600; 73%) 63.5% were men and the mean age ( ± standard 
deviation) was 63.8 ± 6.9 years. Individuals with an increased coronary artery calcification score 
consulted their general practitioner more often compared to increased risk individuals from arm 
A: 140/149 (94%) and 86/137 (62.8%), respectively (P < 0.001). Current use of blood pressure 
and cholesterol-lowering drugs was significantly higher in the increased coronary artery 
calcification score group (108/140; 77.1%), compared to the group with an increased traditional 
risk (35/80, 43.8%; P < 0.001). Self-reported compliance was high (98.1–100%). 
Conclusion: Receiving the screening result might be a teachable moment that can enhance 
cardiovascular disease prevention-seeking behaviour through consulting a general practitioner 
and high compliance with preventive treatment. The impact of the screening result was more 
profound in the increased coronary artery calcification score group. 
 
  




Cardiovascular disease (CVD), including coronary heart disease (CHD), has an enormous global 
burden in terms of both morbidity and mortality, annually accounting for over 30% of all deaths 
worldwide (1, 2). CVD has a long asymptomatic period and is often only diagnosed in a 
progressive phase when serious events occur. This stresses the importance of early detection 
(screening) and subsequent risk-reducing treatment of asymptomatic people to stop or delay 
subclinical disease progression (3). Risk stratification is currently based on risk prediction models 
including the main traditional risk factors, and distinguishes low, intermediate and high-risk 
individuals (4-7). However, the amount of coronary artery calcification (CAC), which is strongly 
related to all-cause and CHD-related mortality, is suggested to be more accurate in risk 
stratification (8-10). In addition, recent evidence suggests a high external validity of CAC 
screening in a population-based prospective cohort in terms of cardiovascular risk (11). The 
availability of risk stratification tools and effective preventive measures, such as modifying 
lifestyle behaviour and preventive medication, suggests that population-based screening might 
be a promising strategy in secondary prevention (3, 12). The Dutch Risk Or Benefit IN Screening 
for CArdiovascular disease (ROBINSCA) trial is the first large population-based randomised 
controlled screening trial designed to investigate whether screening for a high CVD risk by 
means of either traditional risk assessment (arm A) or quantifying CAC using computed 
tomography (CT) scanning (arm B) followed by preventive treatment can reduce CHD-related 
morbidity and mortality in asymptomatic high-risk individuals compared to a control group. 
 
For preventive measures to be effective, individuals need to comply with preventive advice 
consistently. Unfortunately, many individuals experience an inability to do so, especially caused 
by the asymptomatic character of CVD (13, 14). However, the moment individuals receive a 
screening result might be a so-called teachable moment; a health event that motivates individuals 
to seek prevention for their increased risk status (15). Previous research on teachable moments 
has shown that participation in a screening programme creates valuable opportunities to advise 
participants about a risk-reducing lifestyle (15, 16). Receiving an unfavourable result can cause 
concern which can change the perceived susceptibility and seriousness of being at risk. The 
higher perceived threat can result in intention for or actual behavioural change by means of 
seeking and complying with preventive measures (13, 17). 
 
In the ROBINSCA trial, risk stratification is communicated to both participants and their general 
practitioners (GPs). Participants with an increased CVD risk are advised to consult their GP for 
preventive treatment. It is currently unknown whether receiving a CVD screening result is a 
teachable moment to seek prevention and to comply with given advice. It is also unknown 
whether there is a difference in impact from receiving the result between two different screening 
methods (arms A and B within the ROBINSCA trial). Finally, health behaviour change is also 
crucial in determining the potential effect of screening in the ROBINSCA trial. Therefore, this 
study investigated the prevention-seeking behaviour after receiving the screening result and 
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This study was conducted in a subsample of participants of the ROBINSCA trial (Figure 1). The 
aim of this randomised controlled trial was to assess whether screening for a high risk of CVD 
reduces CHD morbidity and mortality with 15%. Based on the national population registry, a 
total of 394,058 men aged 45–74 years and women aged 55–74 years from the regions 
Apeldoorn, The Hague and Groningen in The Netherlands were invited to participate between 
2014 and 2016. They were asked to complete a baseline questionnaire and measure waist 
circumference to check eligibility and to sign the informed consent form. Selection of 
asymptomatic individuals took place based on the following inclusion criteria: (a) a waist 
circumference of 88 cm or greater for women or 102 cm or greater for men; (b) a body mass 
index of 30 kg/m2 or more; (c) a family history of myocardial infarction or sudden death before 
the age of 65 years in first or second degree relatives; and/or (d) current smoking. Individuals 
were not eligible when they: (a) were already diagnosed with CVD or had had a CVD surgery; 
(b) received a CAC score measurement in the previous year; (c) use both cholesterol and blood 
pressure-lowering drugs; and/or (d) did not complete the informed consent. In total, 43,447 
eligible individuals were randomly assigned (1:1:1) to the control arm, intervention arm A or 
intervention arm B, and received generic healthy lifestyle recommendations of the Dutch Heart 
Foundation at randomisation. No screening was offered in the control arm. In arm A, the 10-
year risk for fatal and non-fatal CVD was calculated using the systematic coronary risk evaluation 
(SCORE) risk table as adapted for Dutch practice in the Dutch guideline for cardiovascular risk 
management (CVRM) by the Dutch College of General Practitioners (18). This risk prediction 
model is based on age, sex, smoking status, systolic blood pressure and total cholesterol/high-
density lipoprotein cholesterol ratio. A SCORE of less than 10% indicates low CVD risk, 10–
20% indicates intermediate risk and 20% or higher indicates high risk. Participants in arm B 
underwent multi-detector CT scanning for CAC scoring, which is expressed as the total amount 
of any coronary calcifications (Agatston score) (19). CAC scores were stratified into low risk 
(Agatston < 100), high risk (Agatston 100–399) and very high risk (Agatston ≥ 400). After 
screening, both participants and their GPs received the screening result. Participants at increased 
CVD risk were advised to consult a GP for preventive treatment. The treatment study protocol 
was formulated corresponding to current literature and in consultation with the research team 
and local cardiologists and GPs. This treatment protocol advised GPs to treat participants of 
intervention arm A as ‘patients without CVD’ according to the CVRM guideline of the Dutch 
College of General Practitioners consisting of lifestyle advice with complementary lipid and/or 
blood pressure-lowering drug treatment. In intervention arm B, angiotensin-converting enzyme 
inhibitors and statins were recommended for participants at increased risk, which is in line with 
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the CVRM guideline for treating ‘patients with CHD’ (18). All participants are followed for 5 




A random sample of 600 screened participants was recruited from the ROBINSCA trial: 100 
participants per risk stratification category from both intervention arms (Figure 1). The selected 
population received an online questionnaire in which prevention-seeking behaviour and 
compliance with preventive treatment were questioned. Prevention-seeking behaviour was 
considered as behavioural practices regarding (the motivation of) seeking healthcare from a GP 
after receiving the screening result. Compliance was defined as consistently taking prescribed 
preventive medication that should lower CHD-related risk. 
 
 
Figure 1. Flowchart of the study design of the ROBINSCA trial. 
Abbreviations: CAC = Coronary Artery Calcium, CT = Computed Tomography, CVD = Cardiovascular Disease, 






In 2017, participants received an invitation to complete a questionnaire by email including a link 
directing them to the online questionnaire. In this environment, it was possible to skip questions 
because participants might consider some answers as sensitive private data. Participants had at 
least to state their study identification number, date of birth and sex to be able to verify identity. 
Respondents were only included when these background characteristics were filled in as well as 
whether a GP was consulted or not. The questionnaire first asked participants to state their study 
arm and screening result, even though these data were known to the researchers, to investigate 
possible recall bias and the impact of participation. Prevention-seeking behaviour was defined 
as consulting a GP, either on one's own initiative or following a call from the GP. In addition, 
multiple choice questions, including open space to type, were asked about the reasons for 
consulting a GP and the timeframe after receiving the screening result in which this was done. 
There was also a question asked about the reasons for not consulting a GP. Regarding preventive 
measures, it was questioned whether the GP advised on lifestyle changes such as starting a 
healthy diet, reducing weight, increasing physical activity, ceasing smoking and/or reducing 
alcohol consumption. Furthermore, current prescriptions of CVD medication were asked to 
compare with self-reported baseline medication. To measure compliance with preventive 
treatment participants were asked whether they use the current prescribed medication. 
 
Statistical analysis 
Population characteristics from the baseline questionnaire are presented as mean ± standard 
deviation (SD) or median (interquartile range; IQR) as appropriate. Differences in characteristics 
distributions between intervention arm A and B participants and risk subgroups were analysed 
using Pearson's chi-squared test, differences in means of two groups were analysed using the 
independent t-test, and differences in medians between two groups were analysed using the 
Mann–Whitney U-test. Differences in recall of participation, GP visits and preventive CVD 
medication prescriptions after receiving the screening result between low and increased risk 
groups (arm A: SCORE > 10%; arm B: Agatston ≥ 100) were analysed using Pearson's chi-
squared test. A P value of 0.05 or less was considered to be statistically significant. All analyses 




Study population characteristics 
The 600 selected participants received the online questionnaire after a mean ± SD follow-up of 
14.8 ± 3.4 months after screening. The total response rate was 73% (438/600) and the response 
rates of 71% in arm A and 75% in arm B were comparable (P = 0.270). Of all respondents, 
63.5% were men, mean age (±SD) was 63.8 ± 6.9 years, and 43.6% were highly educated. 
Comparing increased-risk and low-risk groups, an increased CVD risk was reported more often 
by men and individuals of higher mean age. About one-third had been diagnosed with 
hypertension (31.5%) or hypercholesterolemia (30.3%) in the past 5–10 years. Both diagnoses 
were reported more often among increased-risk individuals who underwent traditional risk 
screening (arm A). As to health behaviour, 18% were current smokers and 26.7% reported either 
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cholesterol or blood pressure-lowering medication at baseline. The relative amount of smokers 
was higher among individuals at increased risk compared to low risk (arm A: 26.3 vs. 10.5%; 
P = 0.007). There was slightly more self-reported baseline CVD medication use among the 
increased-risk groups compared to low-risk groups (cholesterol-lowering drug use in arm B: 14.9 
vs. 5.3%; P = 0.034) (Table 1). 
 
Prevention-seeking behaviour and compliance with preventive treatment 
Correct recall of the received screening intervention was reported by 82% of the respondents 
from arm A and did not differ between low and increased CVD risk groups (P = 0.859), whereas 
adequate recall in arm B was substantially higher (90.6%) in the increased-risk group compared 
to having a low risk (77.6%; P = 0.008). Recall was significantly higher in the increased CAC 
score group than in the increased SCORE group (P = 0.043). For the screening result, recall was 
higher in low-risk individuals from both intervention arms compared to increased-risk 
individuals (87% vs. 55.6% in arm A; P < 0.001 and 80% vs. 56.1% in arm B; P < 0.001) (Table 
2). Reported recall in the original increased CAC score risk categories was with 38.9% also 
significantly lower in the highest risk group (Agatston ≥ 400) compared to 72.4% in the high-
risk group (Agatston 100–399) (P < 0.001).  
 
As intended, almost no low-risk individuals consulted their GP after receiving the screening 
result (7.9% and 3.9% in arms A and B, respectively). More individuals with an increased CAC 
score (140/149; 94%) consulted their GP compared to individuals with an increased SCORE 
(86/137; 62.8%) (P < 0.001). The most common stated reason for GP consults was the wish to 
reduce CVD risk, especially reported by increased CAC score individuals (86/138; 62.3%) 
compared to increased SCORE individuals (39/86; 46.4%; P = 0.021). Within the increased 
SCORE group, the majority of individuals (52.3%) consulted a GP within one month after 
receiving the screening result. For the increased CAC score group the most stated timeframe 
was one week (48.6%). Increased-risk individuals who did not consult a GP mostly reported no 
health complaints as the reason for not consulting a GP (25/43; 58.1% in arm A and 6/9; 66.7% 
in arm B) (Table 2). 
 
Concerning preventive measures, approximately half of the individuals with an increased-risk 
result received lifestyle advice during the GP consult with no differences between both 
intervention arms (P = 0.350). Initiation of any CVD medication after screening was reported 
by 65 out of 140 (46.4%) increased CAC score individuals, which was significantly higher than 
the 16 out of 80 (20%) individuals with an increased SCORE who had an indication for 
preventive medication based on blood pressure and cholesterol levels (P < 0.001). Total current 
prescriptions of a combination of antihypertensive and cholesterol-lowering drugs were more 
prevalent among individuals with an increased CAC score (67/140; 47.9%) compared to 
individuals with an increased SCORE for whom this medication was indicated (10/80; 12.5%; 
P < 0.001). Also, the total amount of any current CVD medication prescription was significantly 
higher in the increased CAC score group, 108 out of 140 (77.1%), compared to the increased 


















Receiving a screening result when participating in a screening intervention trial such as the 
ROBINSCA trial can introduce a teachable moment to change risk behaviour and seek for and 
comply with preventive measures (15). In the current study, many individuals at increased CVD 
risk indeed showed prevention-seeking behaviour by consulting their GP. This potential 
teachable moment should to be used optimally for CVD prevention by discussing healthy 
lifestyle and preventive treatment options. The Dutch Prevention Consult Cardio Metabolic Risk 
study recently reported on the prevention-seeking behaviour of participants who were invited to 
complete an online CVD risk questionnaire and visit their GP when the questionnaire indicated 
a high-risk result (20). Prevention-seeking behaviour appeared to be twice as low (36%) 
compared to the ROBINSCA trial (63% and 94% in arms A and B) suggesting a potential 
teachable moment after a screening intervention result compared to an online questionnaire 
outcome without testing. As expected in the ROBINSCA trial, CT screening, which is 
uncommon in asymptomatic individuals, was taken more seriously than traditional risk 
assessment resulting in more prevention-seeking behaviour. The traditional assessment includes 
frequently used measures that are part of standard procedure in Dutch general practices, which 
 
Table 3. Preventive measures and compliance with preventive treatment of participants who consulted their general 
practitioner.  
 Intervention arm A 
SCORE 
Intervention arm B 
CAC-score 
 
 Increased risk a 
n/N (%) 




Lifestyle advice b c  45/84 (53.6) 65/138 (47.1) 0.350 
Initiation of CVD medication c d 16/80 (20) e 65/140 (46.4) <0.001*** 
Total current CVD medication (after 
screening) 
   
   Blood pressure lowering  27/80 (33.8) e 82/140 (58.6) <0.001*** 
   Cholesterol lowering  18/80 (22.5) e 93/140 (66.4) <0.001*** 
   Both CVD medication 10/80 (12.5) e 67/140 (47.9) <0.001*** 
   Any CVD medication  35/80 (43.8) e 108/140 (77.1) <0.001*** 
Compliance to current CVD medication c 35/35 (100) e 104/106 (98.1) f 
***P<0.001 
a Combined increased risk categories (intervention arm A; intermediate and high risk, intervention arm B; high and very 
high risk)  
b Lifestyle advice: healthy diet and/or weight reduction and/or increase physical activity and/or smoking cessation 
and/or reduce alcohol consumption 
c Numbers do not match total number because some participants skipped questions 
d Comparison of any baseline and current CVD medication 
e This group includes only individuals with an indication for preventive treatment based on systolic blood pressure (≥140 
mmHg) or total cholesterol (≥5 mmol/L) levels.  
f Small numbers 
Abbreviations: CAC = Coronary Artery Calcium, CVD = Cardiovascular Diseases, SCORE = Systematic Coronary Risk 
Estimation 
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might have diminished the impact of the screening result. Other reasons for not seeking 
prevention from a GP despite being at increased CVD risk are denial or underestimation of 
being at high risk, not understanding the principle of secondary prevention – the early detection 
and treatment of an increased risk for developing CHD before symptoms occur – and 
subsequent reluctance of medication. Underestimation might also explain that low-risk 
individuals recalled their CVD risk status better compared to individuals at high risk. 
Misperception of a high CVD risk was also reported by Johnson et al. who investigated the effect 
of knowledge of the CAC score on risk perception and health-promoting behaviour change (13). 
 
Regarding preventive CVD medication, relatively more medication initiation and current 
medication was seen in intervention arm B; a possible result from the more serious impact a CT 
result has on willingness to take preventive medication. The greater amount of prescriptions of 
a combination of CVD medication in arm B is a logical result from the treatment study protocol 
in which it was recommended to treat individuals with both angiotensin-converting enzyme 
inhibitors and statins. An explanation for this drug combination being prescribed to only half of 
the individuals with an increased CAC score might be reluctance of individuals to take different 
kinds of medication without health complaints or reluctance of the GP to prescribe based only 
on CAC score. High compliance with prescribed preventive CVD medication is possibly caused 
by increased consciousness and understanding of being at risk of developing CVD. It is 
important to note that the described numbers are relative; the increased CAC score group is in 
fact smaller than the increased SCORE group (data not shown). Therefore fewer participants 
from the first group are advised to consult their GP and consequently absolute CVD medication 
prescription is lower. 
 
Studies investigating the effect of knowledge on the CAC score showed results similar to ours. 
Gupta et al. investigated the relationship between the identification of CAC and starting with 
and adhering to preventive measures (21). The authors concluded that the presence of CAC 
significantly changed health behaviour in terms of an increase in the initiation and continuation 
of preventive medication and healthy lifestyle interventions. Comparable results were also found 
by Johnson et al. when the authors demonstrated that knowledge of the CAC score improves 
health-promoting behaviour in a relatively highly educated population, underlining the potential 
of this teachable moment (13). Besides, they showed that perceived barriers and quality of life 
are significant predictors for behaviour change. McNaughton and Shucksmith (22) reported on 
compliance with lifestyle advice and preventive medication in high CVD risk individuals 
identified during the National Health Service health check in the UK. Here, CVD risk assessment 
is targeted in all asymptomatic individuals between 40 and 74 years old and is carried out by 
calculating a risk score that is comparable with the SCORE model. Out of 23 interviewed 
individuals with a high risk who initiated statin therapy, 18 (78%) were compliant with taking the 
statin after one year. The higher compliance of ROBINSCA participants might be explained by 
the much smaller sample size in the UK study or by the fact that ROBINSCA participants are 
volunteers in a scientific trial with possibly a higher level of health consciousness (healthy 





A possible limitation is the use of self-reported questionnaires in which social desirability bias 
might occur (24). However, we assume this risk to be limited because of the created casual setting 
which allows the respondent to complete the questionnaire at any time and place. A limitation 
might be the relatively long follow-up since screening that might have caused recall bias. Another 
limitation is that it was not investigated to what extent individuals adhere to lifestyle advice from 
their GP. This should be a subject in future behavioural research in the field of CVD screening. 
Another future research topic should focus on health literacy, as previous research showed that 
chronic disease patients are more likely to have lower health literacy (25). Low health literacy 
often involves less healthcare-seeking behaviour, which might have occurred in the ROBINSCA 
trial but was not investigated in the current study. The main strength of this research is the 
conduct of the study. The design of the online questionnaire was convenient for obtaining 
reliable information and its simplicity led to a high response. 
 
Despite the promising results of receiving a screening result as a teachable moment for starting 
prevention, future studies should focus on increasing prevention-seeking behaviour in those who 
are expected to benefit from preventive treatment when CVD screening is demonstrated to be 
cost-effective. Furthermore, research on the health-related quality of life of participants is needed 
as receiving a high-risk result might cause anxiety and even depression (26). 
 
In conclusion, prevention-seeking behaviour among individuals with an increased CVD risk was 
high, especially when the CAC score was quantified. CVD medication prescription following GP 
consultation differed between screening methods and was relatively high with good compliance. 
These results imply that receiving a CVD risk screening result has an important role in health 
behaviour change and therefore the prevention of disease. 
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In the Risk Or Benefit IN Screening for CArdiovascular disease (ROBINSCA) trial, the primary 
aim is to investigate whether screening for a high cardiovascular disease (CVD) risk and 
subsequent preventive treatment in a high-risk population can reduce cardiovascular morbidity 
and mortality. The success or failure of such a population screening program depends on several 
factors as the risk-based selection and randomization of a high-risk population for participation, 
the screening protocol, careful analysis of screening results, screening uptake and treatment 
acceptance and compliance. The general aim of this thesis was to evaluate these secondary 
outcomes of the ROBINSCA trial. This chapter discusses all major findings with its strengths 
and limitations. The chapter also reviews challenges within this research topic and future 
perspectives. Finally, conclusions will be drawn.  
 
Main findings and interpretation  
 
Part 1: The ROBINSCA trial 
In this first part, the ROBINSCA trial and its rationale, study design and recruitment process are 
described in Chapter 2. The research question was: How to conduct a population-based randomized-
controlled screening trial to obtain evidence on the effectiveness of screening for cardiovascular risk in an 
asymptomatic high-risk population? 
 
Findings  
Chapter 2 presented the study protocol of the ROBINSCA trial, which includes a power analysis, 
the predefined inclusion and exclusion criteria for participating in the trial, study protocols for 
the screening tests and the advised preventive treatment. According to the power analysis, a 
sample size of 13,028 per study arm should be sufficient to show a reduction of 15% or more in 
morbidity and mortality, which corresponds to 100,000 CHD-related death and 500,000 CHD-
related hospital admissions in Europe annually (at the time of writing the research proposal). 
After approval by the Minister of Health, 394,058 potential participants based on population 
registries were invited of which 87,866 responded to the questionnaire (response rate of 22.3%). 
In total, 43,447 eligible respondents (49.4%) were randomized (1:1:1) to intervention arm A for 
screening according to the SCORE model (n=14,478; 33.3%), intervention arm B for CAC 
scoring (n=14,450; 33.3%), or the control arm (n=14,519; 33.4%). Baseline characteristics (sex, 
age, educational level, region, BMI, waist circumference, family history of myocardial infarction, 
smoking status, and diabetes mellitus) of the study participants were comparable (p>0.05) 
between the three study arms. 
 
Interpretation 
The sample size fulfilled the requirements of the power analysis, indicating that recruitment was 
successful. This implies that there are sufficient participants in the trial to be able to draw reliable 
conclusions from the results that are not based on coincidence. Future similar studies are needed 
to obtain independent results. Furthermore, the results implied adequate randomization, since 
baseline characteristics between the three study arms were comparable. The population-based 
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design of the trial reduced the risk of self-selection. As a result, potential differences in 
background variables (such as morbidity and mortality, general health e.g.) between the study 
population and the target population who is at high risk for developing CHD are minimized.  
Evidence from large-scale RCTs, indicating that CAC screening for CHD can reduce 
CHD-related mortality and morbidity, is lacking so far. As a consequence, current (inter)national 
guidelines do not yet recommend systematic population-based CAC screening in an 
asymptomatic population. The European Society of Cardiology recommends systematic 
assessment of SCORE in increased risk individuals and additional CAC scoring in individuals 
with moderate SCORE (1). The new 2019 guideline on primary prevention of CVD of the 
American College of Cardiology/American Heart Association recommends considering CAC 
scoring to guide (statin) therapy decisions in adults of 40-75 years of age at intermediate 10-year 
atherosclerotic CVD risk rather than a screening test for all (2). However, if screening for 
cardiovascular risk turns out to be successful, CAC screening is estimated to prevent up to 15% 
of the current CHD-related morbidity and mortality. This corresponds to approximately 94,800 
CHD-related deaths and 460,000 CHD-related hospital admissions in the European Union 
yearly, based on 2015 statistics (3). Data from the ROBINSCA trial will ultimately provide more 
insight in the balance between the harms and benefits of screening for CVD. 
In conclusion, evidence for net-effectiveness of population-based screening for 
cardiovascular risk in an asymptomatic population will possibly enable large-scale 
implementation with large health gains. 
 
Chapter 3 focused on contamination, or in other words, mixing of interventions between study 
arms. Contamination can diminish the estimated potential effectiveness of screening. The 
contamination rate was investigated in a sample of the study population to assure statistical 
power to evaluate the screening effectiveness. The research question was: What is the contamination 
rate in the study arms of the ROBINSCA trial? 
  
Findings  
A random sample (n=700) of 600 screened participants (300 per screening arm and 100 per risk 
stratification category) as well as 100 participants from the control arm received an online 
questionnaire after a median follow-up (interquartile range) of 16.8 (4.7) months. Contamination 
in the ROBINSCA trial was defined as performing an off-study CVD screening intervention in 
randomized participants: measuring CAC score in intervention arm A or in the control arm, and 
measuring both cholesterol and blood pressure in the control arm (examinations are part of 
traditional risk assessment in the SCORE risk model). Measuring both cholesterol and blood 
pressure in intervention arm B was not considered as contamination since these measurements 
can be part of monitoring preventive CVD treatment. The power calculation was based on 20% 
potential contamination. The overall response to the contamination questionnaire was 497 
(71%). Response rates in the intervention arms were significantly higher, with 71% in 
intervention arm A (p=0.026) and 75% in intervention arm B (p=0.002), compared to a response 
rate of 59% in the control arm. The results suggested the contamination rate begin negligible. 
CAC score measurements or a combination of cholesterol and blood pressure measurements as 




arm indicating a contamination rate of 0%. Within intervention arm A, one out of 213 
respondents indicated an off-study CAC score measurement resulting in a contamination rate of 
0.5%. In intervention arm B, 80 out of 225 (35.6%) answers reported a combination of 




There was a substantial risk of contamination in the ROBINSCA trial, because participants of 
the different study arms can be family or neighbors who discuss the screening interventions, visit 
the same GP practice or because of familiarity with the SCORE model or unfamiliarity with 
CAC scoring. A possible explanation for the low contamination rate of 0.5% in the SCORE arm 
is that CAC scoring is not part of standard procedure in CVD prevention. An explanation of the 
absence of contamination in the control arm is that controls were not advised to consult their 
GP and subsequently barely did so. Any GP consults of participants from the control arm were 
on own initiative. The maximum potential contamination rate in intervention arm B was 35.6%: 
a combination of blood pressure and cholesterol measurements was reported by 35.6% of the 
respondents. However, instead of indicating contamination, these measurements can also 
indicate initiation or monitoring of preventive drug treatment. The general treatment advice for 
elevated CAC scores include ACE-inhibitors and statins, as derived from the current guideline 
for ‘patients with CHD’ for Dutch general practice. The reason for following the guideline for 
‘patients with CHD’ is that screening demonstrated coronary disease, even though participants 
with elevated CAC may still be asymptomatic. Regarding potential contamination, GPs might 
have performed a blood pressure or cholesterol measurement to check the diagnostic status of 
blood pressure or lipids at treatment initiation. Furthermore, ACE-inhibitors are contra-
indicated in case of hypotension and therefore, blood pressure needs to be monitored regularly. 
The most common stated reason to consult the GP among intervention arm B participants who 
underwent blood pressure measurements, was the wish to reduce the CVD risk. This might 
indicate that the GP started preventive treatment including treatment monitoring. Our 
hypothesis is that part of the GPs indeed performed a full SCORE assessment as a consequence 
of unfamiliarity with CAC scoring and that another part performed the measurements only for 
treatment monitoring routine after acting on the CAC score result. We expect this distribution 
to be within the limit of 20% contamination. Our results of limited observed contamination are 
in line with those of the lung cancer screening trials Danish Lung Cancer Screening Trial 
(DLCST) and the Dutch-Belgian randomized-controlled lung cancer screening trial (NELSON) 
(4, 5). The researchers conclude that the contamination rate might be underestimated because it 
is possible that some participants who received an off-study intervention do not fulfill the 
questionnaire as they understand that off-study interventions may affect the outcomes of the 
trial. This might have happened within our study as well, although the exact purpose of the 
questionnaire was obviously not mentioned in the general introduction in the invitation to 
prevent social desirable responses. 
In conclusion, the contamination rate in the ROBINSCA trial is expected to be below 
the acceptable predefined rate and therefore is unlikely to affect the power to demonstrate a 
potential effect of early detection and treatment of a high CVD risk.  
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Part 2: Cardiovascular disease screening results 
Chapter 4 described the CVD risk distributions in the screening arms of the ROBINSCA trial. 
The potential reduction in preventive overtreatment was estimated based on the expected 
difference in risk distributions. The research question was: What are the differences in cardiovascular 
risk distributions and the number of preventive treatment indications between screening using traditional risk 
factor assessment or coronary artery calcium scoring in asymptomatic participants of the ROBINSCA trial? 
 
Findings  
Screening attendance rate was high, but different as expected for both intervention arms; 12,185 
out of 14,478 (84.2%) participants underwent a SCORE assessment and 12,950 out of 14,450 
(89.6%) participants underwent CT scanning for CAC quantification (p<0.001). Based on the 
Dutch SCORE, 53.8% (3,234/6,009) of women were classified as low-risk, 24.6% (1,479) as 
intermediate and 21.6% (1,296) as high-risk. A substantial different CVD risk distribution was 
observed using CAC scoring: more low-risk individuals were identified. A zero CAC score was 
measured in 48.0% of the women (2,984/6,223), and 35.3% (2,196) had a low CAC score 
(Agatston 1-99), 12.1% (754) had a high CAC score (Agatston 100-399) and 4.6% (289) had a 
very high CAC score (Agatston ≥400). The absolute reduction in the number of high-risk 
women was 29.4% when CAC scoring was used as screening tool and the relative reduction was 
63.7%. Regarding men, 36.6% (2,262/6,176) were assessed as being at low risk, 28.4% (1,751) 
as intermediate risk and 35.0% (2,163) as high-risk based on the SCORE model. A total of 31.2% 
(2,098/6,727) had a zero CAC score, 38.1% (2,561) had a low CAC score, followed by 17.8% 
(1,200) and 12.9% (868) with a high and very high CAC score respectively. The absolute 
reduction in the number of high-risk men was 32.7% and the relative reduction was 51.5% when 
CAC scoring was used as screening tool. These large differences in CVD risk distributions 
between the screening modalities in both women and men caused statistically significant 
differences in the number of individuals indicated to consult their GP for preventive drug 
treatment. Eventually, the GP will consider drug treatment based on medical background and 
when systolic blood pressure is  >140 mmHg and/or LDL-cholesterol >2.5 mmol/L. Preventive 
treatment was indicated for 26.7% of women according to the SCORE model, compared to 
16.8% of women according to CAC scoring (p<0.001). This caused an absolute reduction of 
9.9% and relative reduction of 37.2% in the number of women indicated for preventive 
treatment when using CAC scoring compared to SCORE calculation. Among men, 43.2% were 
advised to start preventive treatment according to the SCORE model, whereas 30.7% received 
a preventive treatment advice according to CAC scoring (p<0.001). The absolute reduction was 
12.4% and the relative reduction was 28.8%. 
 
Interpretation 
As expected, the results show that the CVD risk distributions differed largely between the two 
screening modalities. CAC scoring identified more low-risk individuals compared to the SCORE 
model. Traditional risk prediction using the SCORE model has several limitations, including the 
limited adaptation for different ethnic groups, the limited age range, and the lack of incorporating 
risk modifiers that potentially reclassify CVD risk, such as socio-economic status, CVD family 




the decision to start preventive treatment is often debatable based solely on SCORE assessment 
(6). As stated before, current European and American guidelines recommend considering 
additional CAC scoring to guide preventive therapy decisions in intermediate-risk adults (1, 2). 
A reason for this is that CAC scoring has superior discrimination and risk reclassification as 
compared with other risk indicators (7). Previous studies showed that asymptomatic 
intermediate-risk individuals were more often downgraded to a lower risk category after adding 
CAC scoring to risk prediction (8, 9). There are no results yet of CAC score and SCORE 
estimates within one individual in the ROBINSCA trial. Future analyses will focus on that. 
However, as baseline characteristics are comparable and the study population size is sufficient, 
it might be reasonably assumed that risk estimates based on SCORE are comparable over the 
three study arms, as well as risk distributions based on CAC score. Therefore, our results are in 
line with the previous studies. Additionally, a review summarized the results of population-based 
cohorts that showed the convincing value of CAC scoring beyond traditional risk factors as a 
single predictive cardiovascular risk marker (10). Recent literature also described that shared-
decision making guided by CAC scoring in intermediate-risk individuals can be a cost-effective 
strategy to avoid years of preventive medication (10, 11). However, there is no evidence yet on 
using CAC scoring as a screening tool for all.  
The substantial reduction in the number of individuals indicated for preventive 
treatment after CAC scoring will potentially influence prevention strategies significantly. The 
CAC score is considered to be an improved estimate of CVD risk status, however, this should 
first be confirmed. If proven, it might minimize unnecessary and unjustified stress that 
potentially occurs when participants receive an unfavorable test result (12). It will also reduce 
the burden for GPs, as risk management based on CAC scoring should be less time consuming 
since the indication for treatment is more clear. Furthermore, the potential reduction in 
preventive overtreatment will reduce potential harmful side effects in participants and costs of 
drug treatment and cardiovascular risk management. However, the effectiveness of CT screening 
in reducing CVD-related morbidity and mortality should first to be confirmed, as CT scanning 
is more expensive compared to using the SCORE model. Moreover, participants are exposed to 
radiation which might cause side effects. We developed a protocol to keep the radiation dose as 
low as possible. The protocol also included a description of clinically relevant incidental findings 
which could be detected on the CT scan. There were few incidental findings during screening, 
as the scans were zoomed in as closely as possible on only the coronary arteries. Future analyses 
on CVD-related events in the ROBINSCA trial might add important evidence on whether CVD 
screening is effective in reducing CHD-related events and to what extent a preventive treatment 
decision should be based on CAC screening. 
 In conclusion, CAC scoring classified significantly fewer individuals at high-risk for 
CVD in both women and men compared to applying the SCORE model. Subsequently, the 
potential reduction in preventive overtreatment might favor the use of CAC scoring in screening 
for cardiovascular risk in the asymptomatic, potential high-risk, population. 
 
Chapter 5 provides more insight in CAC prevalence, distribution and predictors in a high-risk 
potential target population for screening from the general population. The research question 
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was: What is the coronary artery calcium prevalence and what are predictors in an asymptomatic potential high-
risk target population for coronary artery calcium screening? 
 
Findings  
CAC was absent in 39.2% of the total screened study population (n=12,950), in 48% of women 
(n=6,223), in 20.7% of men in the same age category as women (n=4,537) and in 31.2% of all 
men (n=6,727). Further, 16.8% of women had a CAC score of 100 or higher compared to 40.0% 
of men in the same age category and 30.7% of all men. Statistically significant higher CAC scores 
were observed with higher age, low educational level, current smoking, having diabetes, and 
hypertension and hypercholesterolemia in the past year. A low educational level was defined as 
primary, lower secondary general or lower vocational education, medium level as intermediate 
vocational or higher secondary education, and a high educational level was defined as higher 
vocational education or university. The specific CAC score percentiles accentuated the wide 
variations of CAC among sexes and age categories; in particular, CAC development seems to 
differ approximately by ten years and possibly progresses slower in women. Age, educational 
level, high waist circumference, high BMI, family history of CHD, smoking at baseline, diabetes 
mellitus, self-reported hypertension or hypercholesterolemia at baseline, and baseline use of 
either antihypertensive or lipid-lowering medication were all selected as predictors in the 
backward regression analysis of the presence of CAC and in the linear regression for predicting 
the log-transformed CAC extent. The composition of the predictors differed moderately in the 
models for women and men.  
 
Interpretation 
The associations of age, male sex, diabetes mellitus and smoking with higher CAC scores are 
well-known (13-15). In our results, diabetes mellitus was one of the strongest predictors for CAC 
presence in women. This is in line with previous research where diabetes mellitus was identified 
to have a greater impact in women compared to men (16). Moreover, diabetes mellitus was a 
strong predictor for CAC extent in both sexes, suggesting that it is the most important risk factor 
for CAC development after sex and age (17). Current smoking predicted both the presence and 
the extent of CAC in women and men. It is important to realize that the reduction of smoking 
prevalence declined more slowly among women over the past decades and that prolonged 
smoking is more harmful for women regarding CVD outcomes, which therefore requires extra 
awareness (18, 19). Another important predictor besides current smoking might be smoking 
history in terms of pack-years. However, as smoking history of ROBINSCA participants was 
not questioned in the baseline questionnaire, a future study might focus on the potential 
predictive value of this variable. Furthermore, socioeconomic status, indicated by educational 
level, was related to CAC development. A potential explanation for this association might be a 
less favorable lifestyle in terms of smoking, diet and physical activity (20-22). Regarding BMI 
and waist circumference, our results confirm earlier findings that showed that BMI is not a strong 
predictor for presence of CAC, while waist circumference is more predictive of CAC presence 
(23, 24). The predictive value of baseline use of either antihypertensive or lipid-lowering 
medication in CAC development was also seen in previous research. High dose and long-term  




with more CVD events. It is suggested that statins induce plaque repair, which is associated with 
stabilization of CVD events (25). Future research is required to elaborate on this hypothesis, for 
example by making a follow-up CT scan.  
The target population for CVD screening should include those individuals who are 
most likely to gain healthy life-years from screening and subsequent treatment. All inclusion 
criteria for the ROBINSCA trial (smoking, waist circumference, BMI and a family history of 
CHD) were statistically significant predictors of either the presence of CAC or the severity of 
the calcifications. Furthermore, CAC score percentiles emphasized the substantial differences 
between women and men. A recent study showed that men might benefit more than women 
from adding CAC scores, since men have a higher net reclassification index from adding CAC 
scoring to the traditional risk assessment (26). Therefore, it seems appropriate in CVD screening 
to select women at approximately ten years higher age compared to men. However, there are 
some female-specific risk factors that substantially increase CVD risk, including preeclampsia 
and menopause onset, which should be recommended for future research topics (18). Overall, 
it seems that a large proportion of the targeted high-risk population can be identified from the 
general population using the current inclusion criteria. Future analyses of morbidity and mortality 
will provide more evidence on the (cost-)effectiveness of CVD screening in the ROBINSCA 
trial. 
 The CAC score is also associated with an increased risk for noncardiovascular disease, 
including cancer, chronic kidney disease, and chronic obstructive pulmonary disease (COPD) 
(27). A recent review summarized evidence and technical considerations of combined CT 
protocols for early detection of lung cancer, COPD, and CVD, the “Big-3” diseases, with low-
dose chest CT. Combined screening could be feasible since a single CT scan of the chest area 
can detect the biomarkers for these three diseases: lung nodule growth rate for lung cancer, 
emphysema for COPD and CAC for CVD. Even though smoking cessation remains the most 
effective measure to decrease Big-3 disease burden, the authors stated that lung cancer screening 
might be extended with screening for COPD and CVD to significantly improve the cost-
effectiveness of low-dose lung cancer screening in the future (28). 
 In conclusion, the currently largest population-based RCT for CAC screening in 
asymptomatic middle-aged individuals showed that 30.7% of men and 16.8% of women with a 
CAC score of ≥100 urgently require preventive treatment. These results can help select the 
optimal target population for screening and determine the best risk prediction and prevention 
strategy should screening for a high risk of developing CVD be (cost-)effective. 
 
Part 3: Cardiovascular health behavior 
Receiving a screening result of cardiovascular screening might be a teachable moment to seek 
preventive health care for a high risk and comply to preventive measures. Chapter 6 described 
the impact of receiving the screening result on prevention-seeking behavior. The research 
question was: What is the impact of receiving a cardiovascular disease risk screening result on preventive behavior 







A sample of 600 screened participants received an online questionnaire after a mean follow-up 
of almost 15 months of which 438 responded (73%). The response rates of 71% in intervention 
arm A (SCORE) and 75% in intervention arm B (CAC scoring) were comparable (p=0.270). In 
intervention arm A, 82% of the respondents correctly remembered the received screening 
intervention and recall did not differ between low and increased CVD risk groups (p=0.859). In 
contrast, adequate recall in intervention arm B was substantially higher (90.6%) in the increased 
risk group compared to having a low risk (77.6%; p=0.008). Moreover, recall was significantly 
higher in the increased CAC score-group (90.6%) than in the increased SCORE-group (82.5%; 
p=0.043). Furthermore, recall of the correct risk category was higher in low risk individuals from 
both intervention arms compared to increased risk individuals (87 vs. 55.6% in arm A; p<0.001 
and 80 vs. 56.1% in arm B; p<0.001). Regarding prevention-seeking behavior, almost no low 
risk individuals consulted their GP after receiving the screening result as intended (7.9 and 3.9% 
in arm A and B). More individuals with an increased CAC score (140/149; 94%) consulted their 
GP compared to individuals with an increased SCORE (86/137; 62.8%) (p<0.001). The most 
common stated reason for GP consults was the wish to reduce CVD risk, which was especially 
reported by increased CAC score individuals (86/138; 62.3%) compared to increased SCORE 
individuals (39/86; 46.4%; p=0.021). Increased risk individuals who did not consult a GP mostly 
reported no health complaints as reason for not consulting a GP (25/43; 58.1% in arm A and 
6/9; 66.7% in arm B). Concerning preventive measures, 53.6% of the individuals with an 
increased SCORE and 47.1% with an increased CAC score received lifestyle advice during the 
GP consult (p=0.350). There were more total current prescriptions of a combination of 
antihypertensive and cholesterol lowering drugs according to the study protocol among 
individuals with an increased CAC score (67/140; 47.9%) compared to individuals with an 
increased SCORE for whom this medication was indicated (10/80; 12.5%; p<0.001). Moreover, 
the total number of any current CVD medication prescription was also significantly higher in 
the increased CAC score-group (108/140; 77.1%) compared to the increased SCORE-group 
(35/80; 43.8%; p<0.001). Self-reported compliance with preventive CVD medication was high 
in both increased risk groups (100 and 98.1% in arm A and B). The described numbers are 
relative; the increased CAC score-group is smaller than the increased SCORE-group (data shown 
in Chapter 4). Therefore fewer participants from the first group are advised to consult their GP 
and consequently absolute CVD medication prescription is lower.   
 
Interpretation 
These results showed that a vast majority of the individuals at increased CVD risk showed 
prevention-seeking behavior by consulting their GP. This potential teachable moment should 
be used optimally for CVD prevention by discussing healthy lifestyle and preventive treatment 
options (29). However, the results showed that approximately half of the increased risk 
individuals did not recall their correct CVD risk status. Underestimation might explain that low 
risk individuals had better recall of their CVD risk status compared to individuals at high risk. 
The letter with the screening test result should be as clear and specific as possible to prevent 
denial, underestimation and misperception of being at high risk, as well as not understanding the 




previously performed pilot study, the potential effect of a teachable moment after a physical 
screening intervention was at least twice as high as after completing an online CVD risk 
questionnaire (30). This suggests that performing tests to measure CVD risk has more impact 
than answering questions about the potential risk. As expected, especially CT screening resulted 
in relatively more prevention-seeking behavior compared to traditional risk assessment. This 
might be explained by CT scanning being high-quality equipment compared to blood testing and 
a blood pressure monitor. Furthermore, CT scanning is uncommon in asymptomatic individuals. 
The traditional risk assessment includes frequently used measures that are part of standard 
procedure in Dutch general practices which might have diminished the impact of the SCORE 
screening result. Another possible result from the more serious impact of a CT result is the 
increase in willingness to take preventive medication. Relatively more intervention arm B 
participants reported CVD medication initiation and current medication. At-risk individuals with 
prescribed preventive CVD medication reported high compliance rates. The explanation could 
be an increased consciousness and understanding of being at risk for developing CVD. This is 
in line with previous research that showed that knowledge of CAC presence increased health-
promoting behavior and initiation and continuation of preventive medication and healthy 
lifestyle interventions (12, 31). However, an important note when measuring compliance is the 
potential role of the healthy volunteer effect. Volunteers in a scientific trial possibly have a higher 
level of health consciousness. For example, compliance to preventive treatment was lower after 
CVD risk assessment in asymptomatic individuals in the National Health Service health check 
in the UK (32).  
In conclusion, prevention-seeking behavior among individuals with an increased CVD 
risk was high, especially when the CAC score was quantified. CVD medication prescription 
following GP consultation differed between screening methods and was relatively high with 
good compliance. These results imply that receiving a CVD risk screening result is a potential 
teachable moment and therefore has an important role in health behavior change and prevention 
of CVD.   
 
Strengths and limitations  
 
The major strength of the research in this thesis is the setting of the ROBINSCA trial. The trial 
is a population-based randomized-controlled screening trial. Only this type of research can 
provide evidence of the highest level on effectiveness of screening. The recruitment process of 
participants through the national population registry reached a large population. This strategy 
aims to limit self-selection bias and to stimulate selection of a representative study population. 
Moreover, the random allocation of study participants to study arms minimizes the effect of 
potential confounding factors. The characteristics of randomized participants will be compared 
with Dutch national data to measure generalizability.  
 
Furthermore, the contamination rate in the study arms and compliance to preventive treatment 
were measured with a convenient and straightforward online questionnaire. This allowed 
participants to complete the questionnaire at any time and place they wanted. As a result, the 
response was high and assumed to be reliable. 
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Another strength of this research is the screening protocol. Participants that were randomized 
to the intervention arms received an invitation for screening, either SCORE assessment or CAC 
scanning, at a local screening site. Blood pressure was measured by centrally trained lab staff 
with blood pressure monitors according to the study protocol. Blood samples were also taken 
by trained lab staff and analyzed in an experienced regional laboratory. Furthermore, CT scans 
were made according to a scanning protocol with the lowest radiation dose as possible (33). CT 
images were transmitted to the analyzing center through a secure online environment. This 
prominent center has extensive experience with CAC scans and assessed all scans for the 
presence of CAC. All results were ultimately entered into the data management system. Through 
this system, result letters were sent to participants and GPs in the most error-free manner 
possible. 
 
Despite these strengths, there are some limitations that need to be addressed. The recruitment 
of a high-risk study population was based on self-reported health data rather than diagnostic 
tests. Self-reported data are prone to recall bias and might entail some inaccuracies (34). 
However, each health topic was examined with multiple different questions to determine the 
reliability of answers with more certainty. Therefore, this strategy remains the preferred method 
for recruitment of and data collection from an extensive population like in the ROBINSCA trial. 
In total, 394,058 individuals from the national population registry were invited to participate. It 
would have been unfeasible and not cost-effective to diagnostically verify baseline health 
characteristics of all these individuals. 
 
Regardless the wide reach of potential study participants, the healthy volunteer effect may have 
occurred, making the study population less representative than the target population. It is known 
that study participants tend to be generally healthier than non-responders. Previous research 
showed that individuals who might gain most from screening are least likely to participate (35). 
However, the ROBINSCA inclusion- and exclusion criteria selected participants based on having 
at least one risk factor for developing CVD. This strategy should have minimized the healthy 
volunteer effect as much as possible. An additional related determinant is health literacy. Low 
health literacy is associated with presence of risk factors, poor adherence to treatment and low 
screening attendance and might result in exacerbating health inequalities (36). Health literacy was 
not investigated in this thesis.  
 
Further, the ROBINSCA population is not representative of all ethnic groups. First, only self-
reported data on country of birth of both the participants as well as their parents are known. 
This information provides a reasonable estimate of ethnicity, but classification based on country 
of birth is not always correct. Second, the majority of the study population was native Dutch, 
whereas 18% of the general population within the same age range in the Netherlands have a 
migration background (37). Ethnicity plays an important role as it is known that CAC 
distributions differ among ethnicities (13). As a result, the outcomes may be less generalizable 





An additional limitation is the potential social desirability bias that might have occurred in the 
questionnaire (34). In particular, the questions on the use of prescribed medication or other 
preventive measures might be prone to this type of bias, since individuals understand that 
preventive measures might improve risk status. However, self-reported adherence measures 
through computer administration are the preferred method to obtain reliable data as it reduces 
the risk of biases (38). Furthermore, recall bias was another potential source of bias in the 
questionnaire on contamination and impact of receiving a screening test result. A relatively long 
follow-up since screening may have caused problems in recalling whether or not participants 
consulted their GP after receiving the screening test result. In contrast, it seems reasonable to 
expect that a GP consult following participation in a screening program will have some impact 
on participants, as participating in a screening program is not a common activity. 
Communication to participants is of great importance to achieve sufficient impact and to 
encourage participants to act appropriately on the screening result.  
 
Finally, the contamination rate and the impact of a CVD risk screening result were investigated 
in a relatively small sample of the total ROBINSCA study population. However, we assume that 
the results are relatively generalizable to the study population, since they do not differ on baseline 
characteristics and the response rate was sufficient.  
 
Challenges and future directions  
 
The final analyses of the ROBINSCA trial aim to establish whether population-based screening 
for a high risk of CVD and subsequent early treatment can reduce CHD-related morbidity and 
mortality. After completion of at least 5-years follow-up, data on CHD-related events will be 
obtained through linkages with the national Causes of Death registry and the National Hospital 
Discharge Registry of Statistics Netherlands. Primary outcome analysis of these data allows for 
investigation of screening effectiveness. This analysis should also include subgroup analyses for 
specific risk groups, such as women with female-specific risk factors, diabetics and smokers. The 
risk-based recruitment of participants selected an asymptomatic population who is expected to 
benefit most from screening and early treatment. This selection method attempts to ensure that 
those who do not benefit from screening are not exposed to the potential harmful effects of 
participation. The subgroup analyses should confirm whether the selected risk groups indeed 
benefit most from participating in cardiovascular screening. Future research on the effect of 
ethnicity is recommended as well. Moreover, morbidity and mortality data are necessary to verify 
the reduction in overtreatment when using CAC scoring as screening tool. In this thesis, the 
reduction in the number of individuals indicated for preventive treatment was estimated based 
on their CVD risk status. However, morbidity and mortality analyses should demonstrate 
whether individuals who were indicated for preventive treatment actually have fewer CHD-
related events. These results might add important evidence about whether CAC screening should 
guide decisions on preventive treatment.  
 
As described before, participants of screening trials might be slightly healthier compared to 
nonparticipants which is known as the healthy-volunteer effect. This effect may impair the 
General discussion 
147 
generalizability of the study results to the target population. Therefore, it should be investigated 
whether there are differences between the baseline and mortality characteristics of trial 
participants and nonparticipants.  
 
The potential effectiveness of CVD screening program depends on several factors. After the 
screening performance itself, it is essential that GPs act according to the advice for treatment. 
Participants at (very) high risk for developing CVD are advised to consult their GP who has 
access to their medical background with potential indicators for treatment or contra-indicators 
that should impede treatment as advised. More protocoled treatment options are needed for a 
high-standard screening program, although in this stage the first step is to investigate whether 
the early detection of a high risk in the asymptomatic population is feasible. The final decision 
regarding preventive treatment is made in consultation with the GP and not solely based on the 
ROBINSCA advice for treatment. Shared-decision making is important in a screening program, 
as each individual has an unique medical background that either indicates or contraindicates drug 
treatment. However, this may have consequences for demonstrating the effect of screening. The 
final outcomes not only depend on the effectiveness of the screening modality, but also on 
appropriate subsequent response in terms of preventive (drug) treatment. The shared-decision 
making process increases the workload of GPs as cardiovascular risk management might be time 
consuming. On the other hand, accurate risk management will reduce morbidity and will 
therefore provide long-term benefits. Clear information and evidence should be communicated 
to GPs to explain importance. Adherence to the protocol is important to ensure that those who 
are expected to benefit most from screening and early treatment actually receive preventive 
treatment. Future research should investigate the adherence of GPs to the advice for treatment. 
Second, as previously described in this thesis, prevention-seeking behavior and compliance to 
preventive measures of participants are also crucial in achieving a reduction in CHD-related 
events. Since it was not investigated to what extent participants adhered to lifestyle advice, this 
should be explored in future research. This research should also include improving strategies to 
stimulate prevention-seeking behavior and the role of health literacy in compliance to preventive 
measures.  
 
Should CVD screening be effective, potential adverse side effects need to be considered before 
implementing a screening program. First, screening can cause psychological side effects, such as 
discomfort, anxiety and distress related to screening. The impact of screening on health-related 
quality of life (HRQoL) should be included in balancing the overall favorable and unfavorable 
effects of screening. HRQoL and general anxiety will be assessed in a subsample of the 
ROBINSCA trial. Second, individuals are exposed to a radiation dose in CAC screening. To 
avoid side effects from radiation, the effective dose should be as low as possible. An imaging 
protocol was developed for the ROBINSCA trial (33). However, validation of the protocol is 
needed and the impact on CAC score of different CT generations should be investigated.   
 
Finally, a cost-effectiveness analysis should be performed after the above analyses have been 
completed. A microsimulation screening analysis (MISCAN) model will be developed for the 




dynamic populations, to explain results of screening trials, to predict and compare the (cost-) 
effectiveness of different screening policies and to monitor the results of population screening 
programs (39). The HRQoL measures will be used to calculate quality-adjusted life-years gained 
for implementation in the cost-effectiveness analysis. Furthermore, direct and indirect costs for 
all the phases (screening, diagnosis, preventive treatment, advanced disease) will be obtained and 
used in the micro-simulation model to estimate the cost-effectiveness of cardiovascular 
screening. Cost-effectiveness is calculated as the difference in total costs between a situation with 
screening and a situation without screening, divided by the difference in life-years. Cost-
effectiveness should be calculated for different screening scenarios, varying in screening interval, 
screening age, screening modality and target group. As described in this thesis, only one 
screening round is performed in the ROBINSCA trial. Additional research should focus on 










Final conclusions and recommendations  
 
Conclusions following the research in this thesis are: 
 
 Evidence for net-effectiveness of population-based screening for cardiovascular risk in 
an asymptomatic population is lacking. However, the ROBINSCA trial was designed 
adequately to provide evidence on the effectiveness of screening, which is expected to 
enable large-scale implementation with large health gains if effective. 
 
 The contamination rate in the ROBINSCA trial is expected to be below the acceptable 
predefined rate. Since an adequate randomization and a sufficient sample size were also 
achieved, it is likely that the trial has sufficient power to demonstrate a potential effect 
of early detection and treatment of a high CVD risk. 
 
 CAC scoring classified significantly fewer individuals at high-risk in both men and 
women, as compared to using the SCORE model. Subsequently, fewer individuals were 
indicated for preventive drug treatment, which potentially indicates a substantial 
reduction in preventive care. The risk-based selection of participants detected those 
who benefit most from screening and early treatment.  
 
 The ROBINSCA trial showed that male sex and increasing age, followed by diabetes 
mellitus and smoking, influence CAC distribution to a large extent. Further, 30.7% of 
men and 16.8% of women with a CAC score of ≥100 are recommended for preventive 
treatment. A large proportion of the targeted high-risk population will be identified 
using the defined inclusion criteria for participation in the trial.  
 
 Receiving a CVD risk screening result is a potential teachable moment and results in 
high prevention-seeking behavior among individuals with an increased CVD risk, 
especially when the CAC score was quantified. CVD medication prescription following 
GP consultation was higher after CAC quantification but was relatively high with good 
compliance in both screening arms.   
 
Specific recommendations based on these conclusions are: 
 
 The primary outcome analysis using data on CHD-related morbidity and mortality 
needs to be performed after at least 5-years of follow-up. This analysis should 
preferably include analyses of subgroups such as postmenopausal women, diabetics, 
smokers, and different ethnic groups.  
 
 To examine the generalizability of the results, it is required to compare baseline and 




 The potential effectiveness of CVD screening partly depends on adherence of GPs to 
the advice for treatment. It should be monitored whether tools are required for 
improved communication of background information and clinical relevance. 
Education of GPs on the treatment protocol is essential.  
 
 Given the low costs of lifestyle changes compared to preventive drug treatment, future 
research should investigate the impact of screening on willingness to adhere to lifestyle 
changes. This research should also include the role of health literacy in compliance to 
preventive measures. 
 
 Cardiovascular screening can cause adverse side effects. Research on health-related 
quality of life and general anxiety is needed to balance favorable and unfavorable effects 
of screening.  
 
 Follow-up CT scan might add important knowledge on progression of CAC after CAC 
scanning and potential subsequent preventive treatment. Funding for these follow-up 
scans is urgently needed.  
 
 Ultimately, a cost-effectiveness analysis should be performed after the above analyses 
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Cardiovascular disease (CVD) is the main cause of death worldwide and is responsible for 45% 
of all annual deaths in Europe. Approximately one fourth of the CVD burden is caused by 
coronary heart disease (CHD). Improving the modifiable lifestyle risk factors or starting 
preventive drug treatment can reduce the risk of developing CVD. However, a problem in 
preventing cardiovascular events is that a large proportion of the population is missed for 
preventive measures.  
 
CHD is often asymptomatic for a long time until serious events occur and effective and 
affordable risk-reducing medication is available. This offers opportunities for early detection 
(screening) and subsequent treatment of an increased risk of CVD. However, large-scale 
randomized controlled trials (RCT) to investigate the effectiveness of screening for a high CVD 
risk are lacking. Furthermore, there is no evidence yet on what the most suitable screening tool 
should be. The first population-based RCT on screening for a high risk of CVD (ROBINSCA 
trial) was initiated to investigate the effectiveness of cardiovascular screening by means of risk 
assessment based on traditional risk factors or coronary artery calcium (CAC) quantification 
using computed tomography (CT) scanning. The purpose of this thesis was to evaluate several 
secondary outcomes of the ROBINSCA trial in terms of investigating the conduct of the risk-
based selection and randomization of a high-risk population for participation, the screening 
protocol, careful analysis of screening results, screening uptake and treatment acceptance and 
compliance. 
 
Part 1: The ROBINSCA trial 
In Chapter 2, the rationale, study design, and the recruitment process of the ROBINSCA trial 
were described. The detailed descriptions included a power analysis, the predefined inclusion 
and exclusion criteria for participating in the trial, study protocols for the screening tests and the 
advised preventive treatment. The results implied a successful recruitment, since the sample size 
fulfilled the requirements of the power analysis, and adequate randomization, since baseline 
characteristics between the three study arms were comparable. If screening for cardiovascular 
risk turns out to be successful, CAC screening is estimated to prevent up to 15% of the current 
CHD-related morbidity and mortality. Evidence from the ROBINSCA trial will ultimately 
provide more insight in the balance between the harms and benefits of screening for CVD and 
will possibly enable large-scale implementation with large health gains for an asymptomatic 
population.  
 
The aim of the second research question was to investigate the contamination rate in the study 
arms of the ROBINSCA trial (Chapter 3). Contamination, or in other words mixing of 
interventions between study arms can diminish the estimated potential effectiveness of 
screening. A random sample of participants (n=700) of the control arm, intervention arm A with 
screening by traditional risk assessment and intervention arm B with screening  by CAC 
quantification received an online questionnaire about medical examinations that were performed 
by general practitioners (GP) after screening. The contamination rates in the control arm and 
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intervention arm A were (almost) zero. The maximum potential contamination rate in 
intervention arm B was 35.6%, however, the performed measurements can also indicate 
initiation or monitoring of preventive drug treatment. Future results of the ROBINSCA trial 
should demonstrate the potential effect of screening for a high risk of CVD.  
 
Part 2: Cardiovascular disease screening results 
In Chapter 4, the CVD risk distributions in both screening arms were investigated, based on 
risk categories for the screening setting for early detection of preclinical disease. The risk 
distributions based on traditional risk assessment using the systematic coronary risk evaluation 
(SCORE) model and CAC screening were compared. The subsequent potential reduction in 
preventive overtreatment was estimated based on the expected shift in CVD risk distribution. 
Screening uptake was 84.2% in the traditional risk assessment arm and 89.6% in the CAC scoring 
arm. According to CAC screening, significantly more asymptomatic individuals were at low risk 
for developing CVD compared to SCORE screening. This resulted in relative reductions of 
increased-risk individuals of 63.7% and 51.5% in women and men respectively. Subsequently, 
CAC scoring significantly reduced the number of individuals indicated to consult their GP for 
preventive treatment compared to SCORE (relative reduction women: 37.2%; men: 28.8%). 
Future analyses are required to confirm the effectiveness of CAC screening for reduction of 
CHD and to what extent a preventive treatment decision should be based on CAC screening. 
 
In the next chapter (Chapter 5), the CAC prevalence and its predictors in the asymptomatic 
high-risk ROBINSCA-population were investigated. A total of 12,950 men and women (median 
age 62 years) underwent CT scanning for CAC scoring. Absolute CAC score distributions were 
calculated by sex, age and education. A two-step regression approach, including logistic 
regression for presence of any CAC and linear regression of the log-transformed CAC score for 
the severity of CAC present, was used to identify relevant predictors. CAC was absent in 48% 
of the women compared to 31.2% of all men and CAC score was ≥100 (Agatston) in respectively 
16.8% and 30.7%. Men had substantially higher CAC scores: median CAC score was respectively 
17 and 1. Diabetes mellitus, age and smoking were the strongest predictors for presence of CAC 
in women, and age, hypertension and CHD family history in men. Age per ten years and diabetes 
mellitus were the strongest predictors in both women and men for the severity of CAC. These 
results from currently the largest population-based CAC screening study in asymptomatic 
middle-aged men and women, showed that 30.7% of men and 16.8% of women with a CAC 
score of ≥100 urgently require preventive treatment. The results are important to determine the 
best risk prediction and prevention strategy should screening for a high risk of developing CVD 
be (cost)-effective. 
 
Part 3: Cardiovascular health behavior  
The last research question aimed to investigate the impact of receiving a cardiovascular disease 
screening result on preventive behavior and compliance to preventive treatment in asymptomatic 
participants of the ROBINSCA trial (Chapter 6). A random sample (n=600) of participants with 
a screening result received an online questionnaire to measure the impact of a cardiovascular 




groups. The response rate was 73%. Individuals with an increased CAC score consulted their 
general practitioner more often compared to increased risk individuals from arm A: 94% and 
62.8%, respectively. Current use of blood pressure and cholesterol-lowering drugs was 
significantly higher in the increased CAC score group (77.1%), compared to the group with an 
increased traditional risk (43.8%). Self-reported compliance was high (98.1–100%). The results 
indicate that receiving a CVD risk screening result might be a potential teachable moment. The 
impact was more profound in the increased CAC score group. Therefore, risk communication 
has an important role in health behavior change and prevention of CVD.   
 
Discussion and conclusions  
The main findings and answers to the research questions were discussed in Chapter 7. 
Furthermore, strengths and limitations of the research were discussed in this chapter, as well as 
challenges and future perspectives. Based on these considerations, specific recommendations 
were described. The first part of this thesis described that evidence for net-effectiveness of 
population-based screening for cardiovascular risk in an asymptomatic population is lacking. 
Therefore, the ROBINSCA trial was designed adequately to provide evidence on the 
effectiveness of screening. This is expected to enable large-scale implementation with large 
health gains if effective. Furthermore, the results showed that the contamination rate in the trial 
is expected to be below the acceptable predefined rate. Since an adequate randomization and a 
sufficient sample size were also achieved, it is likely that the trial has sufficient power to 
demonstrate a potential effect of early detection and treatment of a high CVD risk. In the second 
part of this thesis, the first cardiovascular disease screening results were shown. The results 
indicated that CAC scoring classified significantly fewer individuals at high-risk in both men and 
women, as compared to using the SCORE model based on traditional risk factors. Subsequently, 
fewer individuals were indicated for preventive drug treatment, which potentially indicates a 
substantial reduction in preventive care. The risk-based selection of participants detected those 
who benefit most from screening and early treatment. Furthermore, results from the 
ROBINSCA trial showed that male sex and increasing age, followed by diabetes mellitus and 
smoking, influence CAC distribution to a large extent. 30.7% of men and 16.8% of women with 
a CAC score of ≥100 are recommended for preventive treatment. A large proportion of the 
targeted high-risk population will be identified using the defined inclusion criteria for 
participation in the trial. The research in the third part of this thesis showed that receiving a 
CVD risk screening result is a potential teachable moment and results in high prevention-seeking 
behavior among individuals with an increased CVD risk, especially when the CAC score was 
quantified. CVD medication prescription following GP consultation was higher after CAC 























Hart- en vaatziekten ziekten (HVZ) zijn wereldwijd de voornaamste doodsoorzaak en 
veroorzaken 45% van alle jaarlijkse sterfgevallen in Europa. Ongeveer een kwart van de 
cardiovasculaire ziektelast wordt veroorzaakt door coronaire hartziekten (CHZ). Het verbeteren 
van de aanpasbare risicofactoren in de leefstijl of het starten van preventieve medicamenteuze 
behandeling kan het risico op het ontwikkelen van HVZ verminderen. Echter het feit dat een 
groot deel van de bevolking gemist wordt voor preventieve maatregelen geeft een probleem bij 
de preventie van cardiovasculaire aandoeningen.  
 
CHZ zijn vaak lange tijd asymptomatisch totdat zich een ernstige ziekte voordoet. Er is 
effectieve en betaalbare risico verlagende medicatie beschikbaar. Dit samen biedt kansen voor 
vroege opsporing (screening) en behandeling van een verhoogd risico op HVZ. Grootschalige 
gerandomiseerde gecontroleerde studies (RCT) ontbreken echter die de effectiviteit van 
screening op een hoog risico op HVZ aantonen. Bovendien zijn er nog geen aanwijzingen over 
wat de meest geschikte screeningstool zou moeten zijn. Het eerste gerandomiseerde 
bevolkingsonderzoek naar screening op een hoog cardiovasculair risico (de ROBINSCA studie) 
is geïnitieerd om de effectiviteit van cardiovasculaire screening te onderzoeken. Hierbij is 
screening uitgevoerd door middel van enerzijds een risicobeoordeling op basis van traditionele 
risicofactoren of anderzijds kwantificering van kransslagaderverkalking (CAC) met behulp van 
een CT scan. Het doel van dit proefschrift was om verschillende secundaire resultaten van de 
ROBINSCA studie te evalueren, waaronder het onderzoeken van het wervingsproces (risico-
gebaseerde selectie en randomisatie) van de onderzoekspopulatie met een mogelijk verhoogd 
risico en het screeningprotocol, en het zorgvuldig analyseren van de screeningresultaten, de 
aanvaarding van screening en de acceptatie en naleving van preventieve behandeling. 
 
Deel 1: De ROBINSCA studie 
In hoofdstuk 2 zijn de aanleiding, de onderzoeksopzet en het wervingsproces van de 
ROBINSCA studie beschreven. De gedetailleerde beschrijvingen omvatten een power analyse, 
de gedefinieerde in- en exclusiecriteria voor deelname aan de studie, de studieprotocollen voor 
de screeningstests en de geadviseerde preventieve behandeling. De resultaten duidden een 
succesvolle werving, gezien het feit dat de steekproefomvang voldeed aan de vereisten van de 
power analyse, en een adequate randomisatie, aangezien de baseline-kenmerken tussen de drie 
studiearmen vergelijkbaar waren. Als screening op cardiovasculair risico effectief blijkt te zijn, 
zal naar schatting tot 15% van de huidige CHZ-gerelateerde morbiditeit en mortaliteit 
voorkomen kunnen worden door CAC screening. Bewijs uit de ROBINSCA studie zal 
uiteindelijk meer inzicht geven in de balans tussen de voor- en nadelen van screening op HVZ. 
Bewijs van effectiviteit kan een grootschalige implementatie mogelijk maken met veel 
gezondheidswinst voor een asymptomatische populatie. 
 
Het doel van de tweede onderzoeksvraag was om het percentage van contaminatie in de 
studiearmen van de ROBINSCA studie te onderzoeken (hoofdstuk 3). Contaminatie, of met 
andere woorden, het mengen van interventies tussen studiearmen kan de geschatte potentiële 
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effectiviteit van screening aantasten. Een willekeurige steekproef van deelnemers (n=700) uit de 
controle arm, interventie arm A met screening door traditionele risicobeoordeling en interventie 
arm B met screening door CAC kwantificatie ontving een online vragenlijst over medische 
onderzoeken die uitgevoerd zijn door hun huisarts na de screening. De contaminatie percentages 
in de controle arm en interventie arm A waren (bijna) nul. Het maximale mogelijke contaminatie 
percentage in interventie arm B was 35,6%. Echter, de uitgevoerde metingen kunnen ook duiden 
op initiatie of monitoring van preventieve medicamenteuze behandeling. Toekomstige resultaten 
van de ROBINSCA studie moeten het potentiële effect van screening op een hoog risico op 
HVZ aantonen. 
 
Deel 2: Resultaten van cardiovasculaire screening 
In hoofdstuk 4 zijn de HVZ-risicoverdelingen in beide screeningsarmen onderzocht. De 
hiervoor gebruikte risicocategorieën zijn gebaseerd op de screeningsetting voor vroege detectie 
van preklinische aandoeningen. De risicoverdelingen op basis van traditionele risicobeoordeling 
met behulp van het systematische coronaire risicobeoordelingsmodel (SCORE) en CAC-
screening zijn vergeleken. Vervolgens is de daaropvolgende mogelijke vermindering van 
preventieve overbehandeling geschat op basis van de verwachte verschuiving in de 
risicoverdeling. In interventie arm A onderging 84,2% de traditionele risicobeoordeling en in 
interventie arm B onderging 89,6% CAC screening. Volgens CAC screening liepen significant 
minder asymptomatische personen risico op het ontwikkelen van HVZ in vergelijking met 
SCORE screening. Er werd een relatieve vermindering van mensen met een verhoogd risico 
berekend van 63,7% bij vrouwen en 51,5% bij mannen. Hierdoor werden ook aanzienlijk minder 
mensen geadviseerd om hun huisarts te raadplegen voor preventieve behandeling op basis van 
CAC screening in vergelijking met SCORE (relatieve reductie vrouwen: 37,2%; mannen: 28,8%). 
Toekomstige analyses moeten aantonen of  CAC screening daadwerkelijk effectief is in het 
verminderen van CHZ en in hoeverre een beslissing over preventieve behandeling gebaseerd 
moet worden op CAC screening. 
 
In het volgende hoofdstuk (hoofdstuk 5) zijn de prevalentie en voorspellers van CAC 
onderzocht in de asymptomatische ROBINSCA-populatie. In totaal kregen 12.950 mannen en 
vrouwen (mediaan leeftijd 62 jaar) een CT scan om de CAC score te bepalen. De verdelingen 
van de absolute CAC scores zijn berekend voor geslacht, leeftijd en opleiding. Een tweestaps 
regressie benadering (logistische regressie voor de aanwezigheid van een CAC en lineaire 
regressie van de log-getransformeerde CAC score voor de mate van de aanwezige CAC) is 
gebruikt om relevante voorspellers te identificeren. CAC was afwezig bij 48% van de vrouwen 
en 31,2% van alle mannen. De CAC score was ≥100 (Agatston) in 16,8% van de vrouwen en 
30,7% van de mannen. Mannen hadden aanzienlijk hogere CAC scores: de mediane CAC score 
was respectievelijk 17 en 1. Diabetes mellitus, leeftijd en roken waren de krachtigste voorspellers 
voor de aanwezigheid van CAC bij vrouwen, en leeftijd, hypertensie en CHD familiegeschiedenis 
bij mannen. Leeftijd en diabetes mellitus waren de voornaamste voorspellers bij zowel vrouwen 
als mannen voor de mate van CAC. Deze resultaten van momenteel het grootste 
bevolkingsonderzoek naar CAC screening bij asymptomatische mannen en vrouwen van 




CAC score van ≥100 dringend preventieve behandeling nodig hebben. De resultaten zijn 
belangrijk om optimale risicovoorspelling en preventie te bepalen als screening op een hoog 
risico op het ontwikkelen van HVZ (kosten-)effectief blijkt. 
 
Deel 3: Cardiovasculair gezondheidsgedrag  
De laatste onderzoeksvraag richtte zich op het onderzoeken van de impact van het ontvangen 
van een screeningresultaat op preventief gedrag en de naleving van preventieve behandeling bij 
asymptomatische deelnemers van de ROBINSCA studie (hoofdstuk 6). Een willekeurige 
steekproef (n=600) van deelnemers met een screeningresultaat ontving een online vragenlijst om 
de impact van het ontvangen van het screeningresultaat te meten in de lage en verhoogde (arm 
A: risico> 10%; arm B: Agatston ≥ 100) risicogroepen. Het responspercentage was 73%. 
Personen met een verhoogde CAC score raadpleegden vaker hun huisarts in vergelijking met 
personen met verhoogd risico uit arm A: respectievelijk 94% en 62,8%. Het huidige gebruik van 
bloeddruk- en cholesterolverlagende medicijnen was significant hoger in de groep met een 
verhoogde CAC score (77,1%), vergeleken met de groep met een verhoogd traditioneel risico 
(43,8%). Zelf gerapporteerde compliance was hoog (98,1–100%). Deze resultaten impliceren dat 
het ontvangen van een HVZ-risico screeninguitslag een potentieel leerzaam moment kan zijn. 
De impact was groter in de groep met een verhoogde CAC score. Risicocommunicatie speelt 
daarom een belangrijke rol bij de verandering van gezondheidsgedrag en de preventie van HVZ. 
 
Discussie en conclusies  
De belangrijkste bevindingen en antwoorden op de onderzoeksvragen zijn in hoofdstuk 7 
besproken. Verder zijn in dit hoofdstuk de sterke punten en beperkingen van het onderzoek 
besproken, evenals uitdagingen en toekomstperspectieven. Op basis van deze overwegingen zijn 
specifieke aanbevelingen gegeven. Het eerste deel van dit proefschrift beschrijft dat er nog geen 
bewijs is voor de effectiviteit van een bevolkingsonderzoek voor de vroege opsporing van een 
hoog cardiovasculair risico in een asymptomatische populatie. Daarom is de ROBINSCA studie 
geïnitieerd om bewijs te leveren voor de effectiviteit van screening. Wanneer screening effectief 
blijkt, zal grootschalige implementatie van een bevolkingsonderzoek naar verwachting veel 
gezondheidswinst opleveren. Bovendien hebben de resultaten aangetoond dat de mate van 
contaminatie in de ROBINSCA studie naar verwachting onder de acceptabele vooraf 
gedefinieerde waarde ligt. Aangezien de randomisatie ook adequaat bleek en de 
onderzoekspopulatie groot genoeg is, heeft de studie hoogstwaarschijnlijk voldoende power om 
een potentieel effect van vroege opsporing en behandeling van een hoog HVZ-risico aan te 
tonen. In het tweede deel van dit proefschrift zijn de eerste screeningsresultaten beschreven. De 
resultaten lieten zien dat het gebruik van de CAC score significant minder mensen als een hoog 
risico classificeerde bij zowel mannen als vrouwen, vergeleken met het gebruik van het SCORE-
model op basis van traditionele risicofactoren. Als logisch gevolg hiervan werden er minder 
personen geïndiceerd voor preventieve medicamenteuze behandeling, wat mogelijk duidt op een 
substantiële vermindering van preventieve zorg. Door de risico-gebaseerde selectie van 
deelnemers zijn diegenen opgespoord die het meest baat hebben bij screening en vroege 
behandeling. Bovendien hebben de resultaten van de ROBINSCA studie laten zien dat het 
mannelijk geslacht en toenemende leeftijd, gevolgd door diabetes mellitus en roken, de CAC-
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distributie in grote mate beïnvloeden. 30,7% van de mannen en 16,8% van de vrouwen met een 
CAC score van ≥ 100 hebben preventieve behandeling nodig. Zoals verwacht zal een groot deel 
van de beoogde hoog risico populatie worden geïdentificeerd met behulp van de gedefinieerde 
in- en exclusiecriteria voor deelname aan het bevolkingsonderzoek. Het onderzoek in het derde 
deel van dit proefschrift heeft aangetoond dat het ontvangen van een HVZ-screeningresultaat 
een potentieel leerzaam moment teweeg brengt. Dit resulteerde in een hoge mate van preventief 
gedrag bij personen met een verhoogd HVZ-risico, vooral wanneer de CAC score werd bepaald. 
Er waren meer HVZ medicatievoorschriften na CAC-kwantificering, maar het aantal 
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